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Patients living with a spinal cord injury (SCI) often develop chronic neuropathic pain
(CNP). Unfortunately, the clinically approved, current standard of treatment, gabapentin,
only provides temporary pain relief. This treatment can cause numerous adverse side effects
that negatively affect the daily lives of SCI patients. There is a great need for alternative,
effective treatments for SCI-dependent CNP.
Minocycline, an FDA-approved antibiotic, has been widely prescribed for the
treatment of acne for several decades. However, recent studies demonstrate that minocycline
has neuroprotective properties in several pre-clinical rodent models of CNS trauma and
disease. Pre-clinical studies also show that short-term minocycline treatment can prevent the
onset of CNP when delivered during the acute stage of SCI and can also transiently attenuate
established CNP when delivered briefly during the chronic stage of SCI. However, the
potential to abolish or attenuate CNP via long-term administration of minocycline after SCI
is unknown.
The purpose of this study was to investigate the potential efficacy and safety of longterm administration of minocycline to abolish or attenuate CNP following SCI. A severe
spinal contusion injury was administered on adult, male, Sprague-Dawley rats. At day 29
post-injury, I initiated a three-week treatment regimen of daily administration with
minocycline (50 mg/kg), gabapentin (50 mg/kg) or saline.
[v]

The minocycline treatment group demonstrated a significant reduction in below-level
mechanical allodynia and above- level hyperalgesia while on their treatment regimen. After
a ten-day washout period of minocycline, the animals continued to demonstrate a significant
reduction in below-level mechanical allodynia and above-level hyperalgesia. However,
minocycline-treated animals exhibited abnormal weight gain and hepatotoxicity compared to
gapabentin-treated or vehicle-treated subjects.The results support previous findings that
minocycline can attenuate CNP after SCI and suggested that minocycline can also attenuate
CNP via long-term delivery of minocycline after SCI (36). The data also suggested that
minocycline had a lasting effect at reducing pain symptoms. However, the adverse side
effects of long-term use of minocycline should not be ignored in the rodent model.
Gabapentin treatment caused a significant decrease in below-level mechanical
allodynia and below-level hyperalgesia during the treatment regimen. Because gabapentin
treatment has an analgesic effect at the concentration I administered, the results were
expected. However, I also found that gabapentin-treated animals demonstrated a sustained
reduction in pain ten days after treatment withdrawal. This result was unexpected because
gabapentin has a short half-life of 1.7 hours in rodents and previous studies have
demonstrated that pre-drug pain levels return shortly after withdrawal of treatment.
Additionally, the gabapentin-treated animals demonstrated a significant and sustained
increase in rearing events compared with all other treatment groups which suggested that
gabapentin treatment was not only capable of reducing pain long-term but may also
significantly improve trunk stability or improve motor function recovery.
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INTRODUCTION
A traumatic spinal cord injury (SCI) can produce devastating and life changing
neurological deficits. According to an extensive survey conducted in 2009 by the
Christopher Reeve Foundation known as, One Degree of Separation, an estimated 1,275,000
individuals in the United States suffer from the consequences of SCI (1). Aside from loss of
motor function, chronic neuropathic pain (CNP) is one of the most prevalent problems
reported among SCI patients. CNP is predominately defined as a state of long-term
exaggerated pain that is brought about by alterations in the pain processing pathways within
the central nervous system (CNS) and peripheral nervous system (PNS). This most often
occurs as a result of disease or traumatic injury (2),(3),(4),(5). Neuropathic pain manifests
into several types of evoked and non-evoked pain syndromes and significantly impairs the
quality of life and functional recovery of SCI patients for the rest of their lives (6),(2).
Unfortunately, CNP develops in 60%-80% of SCI patients (6),(7).
Currently, there is no cure for CNP and it remains very difficult to treat despite a
growing effort among researchers (8). Unfortunately, drugs prescribed for the treatment of
CNP also cause numerous side effects and, at best, only temporarily relieves symptoms. SCI
patients greatly need a new therapeutic intervention to inhibit CNP and improve their quality
of life. This pre-clinical study will investigate and analyze the FDA-approved drug
minocycline and its potential to reduce and possibly abolish established CNP after SCI.

[1]

Spinal Cord Injury
The United States has the highest number of SCI incidents worldwide, with
approximately 12,400 new cases each year (9). The leading causes of SCI in the United
States are motor vehicle accidents (50%), falls (16%), violent acts (12%) and sports related
injuries (10%) (9). Males are much more likely to acquire SCIs and account for nearly 80%
of all new cases (9). After SCI, patients endure a lifetime of complications such as
neuropathic pain and psychosocial issues in addition to permanent disabilities such as
muscle spasticity and paralysis (7),(10),(11). Unfortunately, several incompletely
understood mechanisms contribute to the wide array of problems associated with SCI. There
are no FDA-approved treatments to restore function after SCI and treatments to relieve
associated symptoms are often insufficient and temporary. Muscle spasticity, a common
secondary problem after SCI may also be linked to a condition called autonomic dysreflexia
which is reported most often when the insult occurs at the fifth and sixth thoracic segments
(12),(13). Autonomic dysreflexia is a severe and debilitating condition characterized by a
rapid attack that causes an enormous increase in blood pressure, shivering, sweating, anxiety
and severe headaches (13).
In addition to enduring the life-changing physical consequences of SCI, the financial
burden for treating the numerous chronic conditions is often overwhelming. Patients usually
take medication, undergo years of physical rehabilitation and require caregivers and medical
devices to help them perform daily functions. Healthcare costs for SCI patients during the
first year of injury can range from $228,000 to $775,000 and cost up to three million dollars
during their lifetime (1).

[2]

The consequences of SCI can vary depending on the severity and location of impact
on the spinal cord. In moderate to severe cases, pathophysiology begins with a primary
injury caused by direct mechanical insult to the spinal cord and is followed by a prolonged
secondary injury phase where damage continues to occur. Primary injury is often due to
contusion and compression forces which are caused by bone and/or disk fragments that
bruise the spinal cord upon impact (14). During the first few hours after injury the patient
may experience a variety of damaging pathological events such as edema, hemorrhaging,
severing of white matter, shearing of blood vessels, and the formation of a necrotic epicenter
(15).
The secondary injury phase occurs days to weeks after injury and can often last years
(15). The pathophysiology consists of ischemia and disruption of blood flow, ionic
imbalances and demyelination, as well as degeneration of axons. Apoptosis of neuronal
tissue, infiltration of peripheral immune cells such as T-cells, neutrophils and macrophages,
and formation of a glial scar also occur in response to injury (15). The pathology of
secondary injury can spread far beyond the necrotic epicenter over many years causing
permanent damage to the tissue surrounding the area of injury and leading to an
environment within the spinal cord that is unfavorable to growth and repair (16),(17).
Figure 1, shown below, displays pathological events during the acute and chronic
phase of injury. The events in the acute and chronic stage of SCI contribute to the permanent
state of damage within the spinal cord that is highly unfavorable to growth and repair.

[3]

Figure 1: Schematic presentation of the pathological events displayed during the acute and
chronic phases of spinal cord injury. Adapted by permission from Macmillan Publishers
Ltd: [Nature] copyright 2008 (18).
One major consequence of SCI is a robust and prolonged inflammatory response.
This complex response serves a dual role by providing both beneficial and deleterious
effects during the acute and chronic phases of injury (15). This becomes a challenging issue
for researchers working towards a treatment for the multitude of damaging consequences
produced by SCI. Researchers work to provide a treatment or cure that will not only reduce
neuronal death but will also promote regeneration of neurons and continue providing a
neuroprotective environment for repair.

[4]

There are several cell populations involved in the process of inflammation after SCI
including astrocytes, microglia, T-cells, neutrophils and monocytes (19). Cell populations
function quickly to remove cell debris from the lesion site and attempt to create an
environment suitable for re-growth of tissue. Meanwhile, other cellular populations
counteract the response by advancing further tissue damage (20).
A major aspect of secondary injury is inflammation. This greatly contributes to the
death of neuronal tissue within the spinal cord (21). For example, resident microglia cells
within the spinal cord can play a beneficial role by becoming activated after injury where
they act as macrophages, removing deleterious and foreign debris (22). However, activated
microglia also begin to release an excessive amount of pro-inflammatory cytokines such as
TNF-α and IL-1β, as well as reactive oxygen species, nitric oxide and proteases that
continuously promote tissue damage within the spinal cord (21) Popovich and Jones, 2003;
(22) Xu et al., 2001). Neurons and glial cell membranes produce arachidonic acid after
CNS/PNS injury. This acid can release metabolic products such as prostaglandins,
leukotrienes and free radicals that are largely associated with inflammation and neural
toxicity (23),(24),(25),(26). Many recent studies stress the importance of targeting proinflammatory molecules in the acute stages of SCI to prevent tissue damage that can occur
as a result of the immune response (27),(28),(20).
Fleming-Norenberg et al. found that activated microglia and macrophages were
abundant up to one-year post-injury with analysis and histology of human cord tissue (20).
Through microarray analysis of spinal cord tissue of rodents in the chronic phase of SCI,
Nesic et al. discovered that there are many significantly up-regulated genes known to be
involved in inflammation and increased expression of glial fibrillary acid protein (GFAP)
[5]

mRNA, a known marker of astrocytes (2). Therefore, inhibiting neuro-inflammation is an
important yet controversial approach for treating patients not only in the acute phase of
injury, but also patients living in the chronic phase of SCI.
Chronic Neuropathic Pain
CNP is a highly prevalent and permanent condition among the SCI population and is
known to affect patients with a moderate injury to patients with total paralysis. In a study of
pain after SCI, it was reported that six months after injury 64% of patients complained of
pain and 21% described the pain as severe (29). In a recent pain review after SCI, 64%-82%
of patients reported painful sensations five years after SCI (30). CNP can occur above,
below and at the site of injury. The onset of at-level neuropathic pain most commonly
occurs within weeks of the initial injury, while the onset of below-level neuropathic pain
occurs months to years after injury (7). There is no clear definition of when above-level pain
appears in the patient population. It is most often described as painful sensations when
touching the face and an increase in sensitivity to cold and hot temperatures (31).
Neuropathic pain can be characterized as spontaneous/non-evoked pain which is
independent of peripheral stimuli or as peripherally-evoked pain which occurs when a
stimulus is applied (7). Peripherally-evoked pain includes specific types of pain responses
termed allodynia and hyperalgesia. Allodynia is described as a painful sensation in response
to a normally non-painful stimulus (31). Hyperalgesia describes an exaggerated painful
sensation in response to a stimulus that normally elicits a significantly reduced pain response
(31). Phantom pain can also manifest in SCI patients with paralysis. Phantom pain is a type
of spontaneous/non-evoked pain which causes patients to experience painful sensations
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where all sensory input is gone (7). CNP syndromes are most often described by patients as
persistent burning, cutting, stabbing, shooting, electrical and piercing pain (7),(31).
Pain is a challenging area to study in humans due to the numerous classifications and
questionnaires developed by researchers and multiple descriptions of pain by patients. In
animal models, the task of measuring pain becomes even more difficult in addition to being
highly controversial. Von Frey hair filaments, thermal testing, and girdle response testing in
a rodent model of SCI measure evoked pain. Researchers are currently unable to directly test
spontaneous/non-evoked neuropathic pain in animals due to the absence of verbal
communication. However, analysis of spontaneous exploratory behavior utilizing a
photobeam activity box can provide some insight into the development of non-evoked pain
in animal subjects.
The mechanisms of CNP are exceptionally complex and not entirely understood.
However, recent studies have identified several contributing factors important for
establishment and maintenance of neuropathic pain after SCI. Neuronal mechanisms
contribute to pain by inducing long-term plastic changes along the pain sensory pathways
(32). Nociceptive signaling begins at peripheral sensory neurons enters the spinal cord
dorsal horn, acting as the first relay for pain transmission (32). In a recent study of pain
behavior in a rodent model of SCI coupled with electrophysiology data, the authors indicate
that the peripheral sensory neurons become hyper-excitable after injury and contribute to an
increase in pain sensation (4),(33). At the level of the spinal cord dorsal horn, increased
glutamate release and prolonged activation of NMDA receptors also play a critical role in
long-term plasticity of pain signals (34). Electrophysiology studies show “central
sensitization” of the spinal dorsal horn neurons correlates with an increased pain response
[7]

after SCI (35),(36). The combination of both sustained hyper-excitability of peripheral
neurons and hyper-sensitization of central neurons sends a robust, amplified response to the
thalamus (33). The intensified sensory interpretation by the thalamus of all the combined
neuronal signals is pain (33).
Studies also suggest that synaptic reorganization such as sprouting in the dorsal horn
occurs after SCI (37). Sprouting of dorsal horn neurons can lead to permanent neuronal
changes and can also amplify pain signal pathways leading to the thalamus
(33),(38),(36),(39). Evidence suggests that changes can also occur in third-order somatosensory neurons (33),(40). Hyper-excitability of thalamic VPL neurons suggests that there
is major reorganization of the synaptic circuits and neuronal pathways after SCI (40).
Furthermore, glial cells, which are normally in an inactive/resting state in healthy
individuals, work to maintain the architecture and homeostasis of neuronal cells within the
spinal cord (41). However, upon activation due to SCI, glial cells (astrocyte and microglia
subtypes) increase in cell volume, become thickened and display characteristic “ramified
branches” (41),(36). Permanent activation leads to increased proliferation of glial cells and a
continuous up-regulation of inflammatory cytokine release (41). Once activated, astrocytes
and microglia contribute to CNP through persistent hyper-excitability of the spinal dorsal
horn neurons (2),(35). Chronically activated microglia produce pro-inflammatory mediators
such as IL-1-β, TNF-α, IL-6, MMP-9, MCP-1, TIMP-1 and reactive oxygen species that
contribute to the development and maintenance of CNP after SCI (42),(43),(36),(44).
Evidence from authors of animal studies indicates a strong correlation between pain
sensations and pro-inflammatory mediators released by microglia cells after SCI. For
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example, TNF-α and IL-1β contribute to the development of mechanical allodynia after SCI,
and IL-6 contributes to maintenance of mechanical allodynia (42). The macroglial cells,
astrocytes, are also important in the maintenance and development of pain after SCI.
Astrocytes, in an inactive state and healthy state, provide infrastructure and homeostatic
control of neurotransmitters outside of the synaptic cleft (45). Activated astrocytes
contribute to pain after SCI in numerous pre-clinical studies of CNP after SCI. For example,
Crown et al. provided strong evidence that astrocytes, as well as microglia, have increased
expression of p-38 MAPK enzymatic activity in a rat model of SCI (44). The increased
expression of p-38 MAPK after SCI in the astrocytic cell population plays an important role
in the development of CNP. Inhibition of p-38 MAPK correlates with a decrease in CNP as
well as improved locomotor recovery after SCI (44).
Glial cells also prevent down regulation of GAD-65 in the spinal dorsal horn (35).
This suggests that there is a decrease in endogenous inhibitory activity, which could
contribute to hyper-excitability found in the neuronal pathways. The term “gliopathy” is
now used to describe the many maladaptive responses of glial cells after neural injury (45).
Recent evidence suggests that inhibition of glial activation in both astrocytes and microglia
improves the outcome of chronic pain development with early intervention in animal
models of SCI (28),(46),(44).
Treatment
As previously stated, there is no cure for CNP and treatment with common analgesic
drugs is highly inadequate at reducing pain (8). The current, clinically approved treatment
for CNP is gabapentin (47). Gabapentin was developed for the treatment of seizures and is
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labeled as an anti-convulsant drug (48). The mechanism of action is still unclear. However,
recent studies have demonstrated that gabapentin binds to a calcium channel subunit, alpha 2-delta, and reduces calcium influx into cells (49). The reduction of calcium may contribute
to a decrease in excitability by inhibiting transmitters such as glutamate and substance P in
neurons and therefore provides an analgesic effect (50),(51). In a recent study, gabapentin
treatment reduced symptoms of autonomic dysreflexia and muscle spasticity in a rodent
model of SCI. The authors indicated that gabapentin administration (50 mg/kg), two to three
weeks after injury reduced spinal motor reflexes and dysreflexic hypertension (12). The
findings suggest that gabapentin may be producing an effect through more than one
pathway. Therefore, in SCI patients it is beneficial for attenuating pain, but may also be able
to attenuate muscle spasticity and autonomic dysreflexia. Unfortunately, clinical studies
indicate that patients often discontinue use due to the numerous adverse side effects such as
dizziness, confusion, sedation, cost and lack of efficacy (52),(53). Pregabalin, an alternative
to gabapentin, is also currently being used for treatment of CNP (54). Recent clinical studies
have shown pregabalin to be more effective at a lower dosing regimen than gabapentin (54).
However, side effects such as dizziness and somnolence are reported in approximately 30%
of patients (54). Side effects of drugs prescribed for CNP should be minimal because they
can negatively affect patients’ already difficult daily activities and further reduce their
quality of life.
Previous drugs used for treatment of CNP, such as methylprednisolone, have proven
to be ineffective in clinical trials (55). Opioids such as morphine and oxycodone are also
used by patients to relieve pain symptoms (48). However, abuse of opioid drugs is common
and most are considered highly addictive, both physically and psychologically (56).
[10]

Tolerance to opioid drugs occurs rapidly and withdrawal is often a challenge for chronic
users (56). Therefore, opioid drugs are not a primary source of treatment for chronic pain
syndromes associated with CNP. Based on the lack of efficacy and safety of current pain
treatments, novel therapies with minimal or no adverse side effects need to be found for
patients in the chronic stage of SCI who are living with CNP.
Interestingly, several pre-clinical SCI studies have not only shown that neuroinflammation is an important mechanism in the development and maintenance of CNP;
these studies have also demonstrated that there is a significant correlation between
inflammation and neuropathic pain (33),(42),(43). A potentially promising drug to inhibit
CNP in the chronic stages of SCI is an anti-inflammatory drug called minocycline, which
has been FDA-approved since 1971, initially for the treatment of acne (57). Minocycline is a
semi-synthetic, second generation tetracycline antibiotic (58). Importantly, minocycline is a
highly lipophilic molecule allowing it to pass easily through the blood-brain barrier (58).
Access to the blood-brain barrier may be necessary for targeting inflammation that arises
within the CNS. Because CNP likely involves interconnecting pain-processing pathways in
both the CNS and PNS, access to the blood-brain barrier may be imperative when
developing a therapeutic intervention.
Minocycline as a therapeutic agent has become increasingly important due to
efficacy in pre-clinical animal studies and clinical studies treating neurodegenerative
diseases such as ischemia, multiple sclerosis, amyotrophic lateral sclerosis, acute and
chronic spinal cord injury, Huntington’s disease, Parkinson’s disease and Alzheimer’s
disease (58). Minocycline exhibits the ability to be a potent anti-inflammatory and antiapoptotic agent (58),(59). The anti-inflammatory action occurs by minocycline’s ability to
[11]

inhibit activation of microglia and in turn inhibit the release of many pro-inflammatory
cytokines (59). Minocycline also reduces inflammation by inhibiting matrix
metalloproteinases (MMP), whose enzymatic activities are involved in the breakdown of
extracellular matrix and tissue remodeling (60). In addition, minocycline has the capability
of being neuroprotective by preventing apoptosis of neuronal cells through inhibition of
cytochrome-c release from the mitochondria (61),(62).
Previously, clinicians prescribed minocycline for its known antimicrobial activity
and effectiveness against gram-positive and gram-negative infections (63). In more recent
years, minocycline has been used in clinical trials for neurodegenerative diseases such as
acute stroke, acute SCI, and ALS (58). Minocycline is safe and effective for the treatment of
rheumatoid arthritis. Currently, minocycline is prescribed by 18% of rheumatologists for
rheumatoid arthritis (64). Minocycline use for treatment of diseases is becoming
increasingly popular.
In several pre-clinical studies of acute CNS trauma and disease, minocycline has
been proven to be effective in reducing pain symptoms and improving functional recovery
(65),(36),(66),(67),(28),(46). Hains and Waxman et al. showed that minocycline treatment
five days post-injury in a rat model of contusion injury improved pain thresholds using
behavioral assessment over a four week time period (28). Hains and Waxman also found
that minocycline can improve pain withdrawal thresholds after CNP has been established
with a three day dosing regimen of minocycline in a one month post-SCI rat model (36).
While the improvements in pain threshold were shown during the three day dosing regimen
the pre-drug levels of pain returned immediately after withdrawal of minocycline (36). It is
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currently unknown whether long-term administration of minocycline could be beneficial in
reducing or abolishing symptoms of CNP after SCI in a rodent model.
The common side-effects of minocycline include skin complaints, nausea and
dizziness (64). In general, minocycline has a reputation for being safe and well tolerated
among patients who are administered the drug as an oral capsule. However, several case
studies suggest that long-term use of minocycline have included rare, adverse side effects
such as liver damage and autoimmune hepatitis that develop after an average of two years of
use (68),(69),(70),(71),(72). Other studies have indicated rare side-effects such as black
discoloration of the skin, bone and thyroid (73). Recent conclusions reported from a clinical
study on the efficacy of minocycline in patients with amyotrophic lateral sclerosis were
negative. Gordon et al. reported that ALS patients treated with minocycline for nine months
declined more rapidly than those patients who received a placebo (74). Therefore, in future
clinical studies it is important to be cognizant of the potential for adverse side effects that
minocycline may cause, especially for long-term use in patients with CNS trauma or disease.
I performed this study to investigate the potential efficacy and safety of long-term
administration of minocycline to attenuate established CNP and to determine if pre-drug
pain levels return after withdrawal of minocycline in a rat model of early chronic SCI.

[13]

SPECIFIC AIMS
1. Determine whether minocycline can offer sustained relief of established CNP via
long-term delivery.
Using an adult, male, Sprague-Dawley rat model of spinal contusion injury, I
determined whether minocycline could reduce established CNP over a long-term treatment
period. A severe spinal contusion injury was administered at spinal thoracic level ten using
200 kdyne of force. There was four treatment groups, (n=18); minocycline-treated,
gabapentin-treated, vehicle- (saline) treated, and an uninjured, age-matched control group.
Each group underwent direct and indirect neuro-sensory testing prior to SCI and every 2
weeks for 60 days after SCI (day 0). At day 29, administration of either minocycline (50
mg/kg), gabapentin (50 mg/kg), or vehicle (saline) began and continued daily for 3 weeks.
I assessed mechanical allodynia with von Frey hair testing of the hind limbs. Allodynia
and hyperalgesia, above and below the level of injury were assessed with the girdle response
test using von Frey filaments of non-noxious and noxious force.
A decrease in a variety of spontaneous behavioral activity can be a sensitive indicator of
a non-evoked pain state. Therefore, I assessed exploratory locomotor behavior, which
included fine and gross motor movement, time at rest, speed and distance using the
photobeam activity system. The system was a completely objective and non-invasive tool.
The animal subjects were allowed to move freely for 15 minutes, and then analysis of the
software data identified alterations in the behavioral tasks.

[14]

2. Determine

whether

CNP

returns

following

withdrawal

of

minocycline

administration.
The potential of a minocycline treatment to cure CNP or to attenuate CNP via longterm delivery in SCI patients is currently unknown. At day 60, ten days after dosing was
complete, I performed all direct and indirect neuro-sensory testing as previously described. I
determined whether a sustained reduction of CNP had taken place beyond the conclusion of
minocycline administration, which would indicate that minocycline treatment offered longterm relief of established CNP.

3. Compare the potential efficacy and safety of minocycline against gabapentin, the
clinically approved compound used for treatment of CNP.
Finally, I compared the efficacy and safety of minocycline to that of gabapentin, the
current treatment for CNP by analyzing and comparing the minocycline treatment group
to the gabapentin treatment group in all behavioral assessments and any additional
observations made during the experiment. Both treatment groups received the same
dosing regimen (daily for 3 weeks) and same concentration of drug (50 mg/kg) to make
an equal comparison between treatment groups.

[15]

METHODS
Animal Subjects
I used adult, male Sprague-Dawley rats (225-249 grams) purchased from Harlan
Laboratories, Houston, TX) for this study. The University of Texas Health Science Center
Institutional Animal Welfare Committee approved all animal protocols. All lab members
strictly followed the procedures for laboratory animal care and use found in the Institutional,
AALAC, and NIH guidelines. Animal subjects were housed with access to food and water in
the rodent facility at the Center for Laboratory Animal Medicine and Care (CLAMC) at the
University of Texas Health Science Center at Houston.
Surgery
The surgeon anesthetized the animal subjects with an intraperitoneal (IP) injection of
ketamine 80 mg/kg, zylazine 10 mg/kg, acepromazine 0.75 mg/kg before the animals
underwent a laminectomy at the tenth thoracic (T10) spinal segment. Next, the surgeon
administered a “severe” contusion injury with the Infinite Horizons Spinal Impactor device
(Precision Systems and Instrumentation) using 200 kdynes of force and zero dwell time. The
injury model is a successful and well-validated model in the literature and defined by Dr.
Nesic-Taylor at UTMB-Galveston. The surgeon completed the procedure by suturing the
muscle layers together and used surgical staples to secure the skin closed. After surgery, the
animal subjects recovered on heating pads overnight. I administered 3.0 mL subcutaneous
saline injections to prevent dehydration. Animal subjects also received subcutaneous
injections of Baytril (2.7 mg/kg) twice daily for ten days to prevent post-operative infection
and subcutaneous injections of the analgesic buprenorphin (0.1 mg/kg) were administered
[16]

twice daily for five days post-injury. Animals were closely monitored and provided with the
appropriate palliative care including manual bladder expression which was performed twice
daily for approximately 15 days post-injury until reflex bladder function returned.
Drug Administration
Twenty-nine days post-SCI, I divided the injured animals into three treatment
groups. One treatment group (n=18) received a 3 mL IP injection of 0.9% sodium chloride
solution daily for 3 weeks. The second SCI group (n=18) received a 3 mL IP injection of
minocycline (50 mg/kg) daily for 3 weeks beginning at day 29 post-injury. Stock solutions
of minocycline hydrochloride ( 7 mg/mL; molecular weight (MW) of 538.98; TOCRIS
Biosciences, Ellisville, MO) were prepared in 0.9% sodium chloride solution, gently
warmed in a 60° C water bath for 15 minutes, vortexed, and stored at 4° C for use within 2
days. The third SCI group (n=18) received a 2 mL subcutaneous injection of gabapentin (50
mg/kg) daily for three weeks beginning at day 29 post-injury. A stock solution of gabapentin
(10mg/mL; MW=171.2; Santa Cruz, Santa Cruz, CA) was prepared fresh daily by diluting
in 0.9% sodium chloride solution and briefly mixing. The dose concentrations were based on
previously published studies by Hama and Sagen, who described the effectiveness of
gabapentin in reducing pain after SCI (75). In order to make experimental comparisons
between the effectiveness of minocycline and gabapentin, I used the same concentrations for
both treatment groups. A naïve control group (n=18) was also included in this study to
compare to the injured animals and observe the normal behavior trends in non-injured, agematched control animals.
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Hind Limb Locomotor Functional Assay
Recovery of locomotor function following SCI was recorded using the BBB
locomotor rating scale developed by Drs. Basso, Beattie and Bresnahan at Ohio State
University (76),(77). This scale allows the observer to rate hind limb motor function on a
scale of “0,” no movement of hind limbs, to “21,” coordinated gait, while the animal moved
freely in an open field for four minutes. This test ensured reliability of the injury model and
assessed functional recovery of the animal’s hind limbs. Only animals that received a score
of “0” or “1” at day one post-injury were included in the results of this study to ensure only
animals of the same injury level were included.
Von Frey Hair Test
Mechanical allodynia was assessed by the application of von Frey filaments (3.615.18) with increasing stiffness that corresponded to a gram of force applied (0.4 g-18 g) to
the glabrous surface of the hind limb paws (refer to Figure 2B). The animals were
acclimated to the cages for two consecutive days (one hour per day) before baseline testing
began and 30 minutes prior to all testing sessions. The filament was applied perpendicular to
the paw with enough force to bend the filament slightly and held on the hind paw for one
second. A positive response was recorded if the paw was removed immediately or licked
(78),(79). If a positive response occurred, I allowed 30 seconds to pass before the next
filament application. The Dixon up-down mechanical threshold protocol was used to
determine the value at which the animal withdrew its paw 50% of the time for the left and
right hind paws (80),(78). The value corresponded to the mechanical withdrawal threshold
for each animal. Figure 2A, shown below displays the template for recording results of the
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von Frey hair test using the Dixon up-down mechanical threshold protocol. A “0” indicates
no movement and an “x” indicates a positive response. I averaged the values for the left and
right hind paw together for a measure of withdrawal response at each time point. I
performed this test prior to injury for a measure of baseline response and after injury at day
14, day 28, day 42 and day 60.

A

B

Figure 2: (A) Example of a response recording for the left hind limb (on top) and right hind
limb (on bottom) of one animal. Each number indicates an increasing stiffness and force of
the filament from the lowest possible force of 3.61 to the highest force possible of 5.18; (B)
Picture of a 4.13 von Frey filament

Girdle response test
At-level mechanical allodynia and at-level mechanical hyperalgesia were assessed
using a 2-gram non-noxious force (allodynia) and a 26-gram noxious force (hyperalgesia)
with the application of von Frey filaments on the body (81),(82). Prior to the initial baseline
testing session, I allowed the animals to acclimate to the restraint device for 30 minutes for
two consecutive days. I placed the animal subjects in a restraint device and allowed them to
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acclimate for 20 minutes before each testing session began. The restraint device consisted of
seven slits that allowed for easy application of the filaments from left to right on the body at
twelve different locations rostral to the level of injury and sixteen different locations caudal
to the level of injury (Figure 3A). A positive response was an immediate flinching or
vocalization after application of each filament (81),(82). I applied the 2-gram force first at
each location on the body and the 26-gram force second. There was a 5 second delay
between each application of the filament to allow the animal to relax between applications.
The girdle response test was applied to each treatment group at baseline (before SCI), day
14, day 28, day 42 and day 60 and responses were recorded on a grid map (Figure 3B).

A
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B

Figure 3: Girdle Test Grid Map: (A)-A grid map of the body with black dots representing
the location where the 2-gram (non-noxious) and 26-gram (noxious) von Frey filaments
were placed above (12 locations) and below (16 locations) the level of injury. (B)Example of
grid map recording session: “0” is no response, “X” is a flinch reaction, and “V” is a
vocalization response.

Photobeam Activity Box
The photobeam activity box (PAS; San Diego Instruments, Inc) was comprised of
four, clear plastic chambers (40 X 40 X 40 cm) with a series of 32 photo beams that line the
chamber in both the x-axis and y-axis. PAS has been widely utilized to examine exploratory
behavior of rodents in research studies. The system is a completely objective and noninvasive tool for detecting fine and gross motor movements, rearing events, distance, speed
and rest time of the animal subjects over a given period of time. Alterations in locomotor
activity can be used as a sensitive indicator of a pain condition (83),(84). However, I had to
take special precautions when analyzing the data. For instance, a decrease in the distance
traveled by the animal subject could indicate discomfort, illness or drowsiness due to the
drug or a pain state. Therefore, it was critical to be consistent when handling the animals,
standardize all procedures and carefully observe trends in all treatment groups and for each
[21]

animal over time before drawing conclusions regarding PAS results. In this study, each
testing session began at the same time each day (1pm) in a quiet room. I did not permit other
animals or people in the room during active testing sessions. The chambers were cleaned
with cavicide between each session which was important for removing “fear scents” that
other animals could detect (85). I set each animal gently inside each chamber and allowed
to move freely for a total of 15 minutes. The animal’s movement in the x, y and z planes
caused an obstruction in the beam breaks. A software database collected the various
obstructions made by the animal’s movement for analysis.
I assessed all treatment groups at baseline (before SCI), day 14, day 28, day 42 and
day 60 post-SCI. I assessed the distance (centimeters) the animals moved, the average speed
at which the animals traveled (cm/sec), the amount of time the animals were active
(seconds), the total amount of ambulatory movements and the total amount of rearing events
the animals performed during their 15 minutes in the chamber.
Histology
The animals were sacrificed using a 100 mg/kg IP injection of pentobarbital, and a
trans-cardial perfusion was performed using approximately 150 mL of ice-cold buffered
saline with heparin (20 mg/500 mL) followed by perfusion with approximately 300 mL of
4% paraformaldehyde solution. I then dissected the liver from several animal subjects and
placed it in a 50 mL conical tube filled with 4% paraformaldehyde solution for 24 hours and
placed the liver in a 50 mL conical tube filled with 30% sucrose solution for storage at 4° C.
I cut liver sections on a cryostat machine with a thickness of 30µm per section and placed
the sections into tris-buffered saline (TBS) solution. The tissue sections were carefully
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mounted onto subbed glass slides and allowed to dry overnight. I then performed a
hematoxylin-eosin (HE) stain by rinsing slides in distilled water for 2 minutes, staining in
hematoxylin (cat#MHS-128; Sigma Aldrich) for 15 minutes followed by rinsing each slide
in distilled water. The slides were decolorized in acid alcohol for 3 seconds followed by 15
minutes of rinsing in tap water. The slides were counterstained with 10 dips in eosin solution
(cat# 152880250; Acros Organics), dehydrated with a series of ethanol solutions, cleared
with Hemo-D solution, mounted with Cytoseal solution and cover slipped.
I used the Masson’s trichrome for connective tissue kit (cat#26367; Electron
Microscopy Sciences) for staining liver tissue sections. The protocol was performed
according to Sheehan and Hrapchak: Theory and Practice of Histotechnology (St.
Louis.1980, p. 190) with slight modifications to the incubation times to optimize color
saturation.
Immunohistochemistry
Liver tissue sections of 30 µm thickness from the vehicle group (n=1) and
minocycline group (n=2) were incubated for 1 hour at room temperature in a blocking
solution made of TBS (tris-buffered saline) with 0.25% triton containing 5% normal donkey
serum (Jackson Immuno Research 017-000-121). The sections were then incubated
overnight at 4° C in a primary antibody solution. This solution consisted of TBS with 0.25%
triton solution with goat anti- IL-1β (1:1000, R&D Systems) and mouse anti-ED-1/CD-68
(1:500, AbD Serotec). The sections were washed with three rinses of TBS and then placed in
a secondary antibody solution for 3 hours at room temperature. The secondary antibody
solution consisted of TBS with 0.25% triton, Alexa-Fluor 488 donkey anti-goat IgG, H+L
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(1:500, Invitrogen), and Alexa-Fluor 568 donkey anti-mouse IgG (1:500, Invitrogen). The
sections were washed with 3 rinses of TBS and mounted onto subbed glass slides and
allowed to dry overnight. The dried tissue sections were then coverslipped with FluormountG (Fisher).
Statistical analysis
All behavior data was normalized to each animal’s baseline score (% baseline) to
reduce animal to animal variability. Statistical analysis was performed using Sigma Plot
software with a repeated-measures two-way ANOVA test and Holm-Sidak pairwisecomparisons.
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RESULTS
The Basso, Beattie and Bresnahan (BBB) locomotor test was performed on each
animal at day 1, 2, 3, 5, 7 and 14 post-injury to verify that a severe contusion injury was
properly administered (76). The results indicate the naïve-uninjured animals (n=18) scored a
mean of 21 ± 0 at all time points tested. A score of 21 means the animals had normal
locomotor function and gait, which was expected in naïve un-injured animals. Beginning
one day post-injury BBB scores were significantly decreased compared to the naïve animals
(p=0.001), confirming that a severe contusion injury was properly administered in the
majority of the injured animals (Figure 4). The injured animals scored a mean of 0.6 ± 1.7 at
day one post-injury, which means the animals had either no hind limb movement or slight
movement of one joint. Over time, the injured animals developed slight locomotor recovery
of the hind limbs indicated by an increase in score at day 14 with a mean of 11.1 ± 1.9. This
score means the animals had frequent to consistent plantar steps with no forelimb, hind-limb
coordination.
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Figure 4: The BBB locomotor rating scale shows there was no change in the un-injured
naïve group (n=18) over time. The injured animals (n=56) show a significant decrease in
hind limb motor function at day 1,2,3,5,7,10 and 14 after injury compared to the naïve
animals ( * p =0.001 vs. naive). Error bars represent mean ± standard deviation (SD).
In order to establish the development of CNP after injury, the animals were subjected
to a series of behavior testing sessions prior to SCI to determine baseline scores and then
again at day 14 and 28 after injury. Approximately 70% of the animals developed pain by
day 28 post-injury. SCI animals that did not develop pain were excluded from the study,
meaning any animals performing as well or better than they did before injury were excluded.
It was critical to assess only the animals that developed pain prior to treatment in order to
assess treatment-dependent effects on pain. The results of all behavior data were normalized
to each animal’s baseline score following the exclusion of animals that did not develop pain
to reduce animal-to-animal variability. Because of the exclusionary criteria, the number of
animals per group was; naïve (n=18); vehicle group (n=12); minocycline group (n=13);
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gabapentin group (n=13). The final exclusion criteria to eliminate non-pain developing
animals are listed in Table 1.

Test
BBB score
Von Frey Test Data
Von Frey Test Data
Von Frey Test Data
Von Frey, Girdle and PAS
Data
Von Frey and Girdle Data
Girdle and PAS Data

Reason
≥ score 2 at day 1
≥ 100% of baseline at day 14 and 28
≥ 200% of baseline at day 14 or 28
≥ 300% of baseline at any time point

# of animals
4
2
1
4

outlier at multiple time points in data
outlier at multiple time points in data
outlier at multiple time points in data

3
2
1
17 of 56
animals

Total Excluded From Study

Table 1 Exclusion Criteria: Animals that showed lack of pain development after examining
all behavior data were excluded from this study. Seventeen of 56 injured animals were
excluded, which resulted in pain development in 70% of all injured animals (n=56).

Behavior Testing Results
A. Von Frey Hair Test
Below-level mechanical allodynia was measured by the von Frey hair test. The test
was performed by touching von Frey filaments with increasing grams of force (0.4-15 g)
to the glabrous surface of the left and right hind paw for one second. An immediate
withdrawal of the paw or licking of the paw was recorded as a positive response. After
injury (day 14 and day 28), there was a significant decrease in the force required to
induce a positive response compared with baseline scores (p< 0.003; Figure 5). Before
injury, all of the injured animals demonstrated a relatively high withdrawal threshold
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(group mean of 13.8 g ± 5.1 g). After injury, the withdrawal threshold decreased by day
28 (group mean of 5.8 ± 3.6 g). The sensitivity to a lower gram of force required to
induce a positive response indicated the onset of below-level mechanical allodynia. The
naïve un-injured group showed a slight decrease in withdrawal threshold at day 28 and
day 42; however, these results were not significant. After two weeks of daily dosing, the
von Frey hair test was performed again (day 42 testing). Minocycline and gabapentin
significantly increased withdrawal threshold compared to day 14 and day 28 (p<0.007;
minocycline group mean 10.2 ± 5.5 g; gabapentin group mean 9.7 ± 4.8 g). The
withdrawal threshold remained at the same significantly increased level by day 60
compared to day 14 and day 28 (p <0.007; minocycline group mean 10.6 ± 3.9 g;
gabapentin group mean 9.9 ± 3.6 g). The injured vehicle group did not display an
increase in withdrawal threshold at any time point and clearly demonstrated significantly
reduced withdrawal thresholds from day 14 to day 60 compared to baseline (p<0.005;
day 42 vehicle group mean 4.5 ±1.6 g; day 60 vehicle group mean 6.9 ±3.6 g).
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Figure 5 Below-level mechanical allodynia: von Frey hair test calculated with the updown Dixon method. Minocycline and gabapentin resulted in a significant increase in
withdrawal threshold 2 weeks after treatment (day 42) and 10 days after cessation of the
drug (day 60). Error bars display the mean ± SEM. [(*) p<0.005 vs. baseline;
(†) p <0.015 vs. naïve; (#) p <0.007 vs. day 14/28; (##) p <0.005 vs. vehicle]

B. Girdle Response Test
Hyperalgesia and allodynia were measured with the girdle response test on the torso
of the animal below and above the level of injury while stabilized in a girdle restraint
device. Hyperalgesia was measured with a 26-gram von Frey filament. The 26-gram
filament was considered a noxious force to the animals and was applied to the body until
the filament slightly buckled. Allodynia was measured with a 2-gram von Frey filament.
The 2-gram filament is considered a non-noxious/non-painful force. First, the 2-gram
filament was applied as previously described on the animal at sixteen locations below
the level of injury (T10) from left to right and twelve locations above the level of injury
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from left to right. Positive responses were noted as a flinch or vocalization and then
recorded on a grid map. Following the 2-gram force the same procedure was repeated
with the 26-gram force. An increase in the percentage of positive responses after injury
indicated pain development.
The results demonstrate that there was no significant increase in response above the
level of injury when compared to the baseline using the 2-gram von Frey filament.
Therefore, there was no verifiable allodynia demonstrated at day 14 and day 28 above
the level of injury with this test (Figure 6). The naïve group had a significant decrease in
response at day 42.
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Figure 6 Allodynia above the level of injury: There was no increase in positive
responses with a 2-gram force applied above the level of injury in the vehicle,
minocycline or gabapentin treatment groups. The naïve group’s response significantly
decreased compared to day 14. Error bars display the mean ± SEM. (# p =0.002 vs. day
14).
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There was no significant increase in positive responses below the level of injury
using the 2-gram von Frey filament at day 14 and day 28 (Figure 7). Therefore, there
was no demonstration of allodynia below the level of injury with the girdle response test.
At day 60, the vehicle treatment group and gabapentin treatment group demonstrated a
significant decrease in positive responses when compared to day 14 and day 28
(p<0.004).
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Figure 7 Allodynia below the level of injury: There was no increase in positive
responses below the level of injury with 2 grams of force. At day 60, all animal groups
had decreased positive responses. There was a significant decrease in the vehicle and
gabapentin treatment groups at day 60. Error bars display the mean ± SEM. (# p <
0.004 vs. day 14/28).

There was a significant increase in positive responses after injury with application of
the 26-gram von Frey filament above the level of injury at day 14 in all injured animal
groups compared to baseline (p <0.004, Figure 8). The minocycline treatment group
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also demonstrated a significant increase at day 28 (p=0.003). The vehicle and
gabapentin group demonstrated an increased response at day 28; however, it was not
significant. At day 42 of testing, 2 weeks of treatment with minocycline caused a
significant decrease in positive responses when compared to day 14 (p=0.005).This
result was not achieved in either the gabapentin or vehicle group. By day 60, ten days
after dosing was complete (washout period), the minocycline-treated animals continued
to demonstrated a significant decrease in positive responses when compared to day 14
and day 28 (p<0.001). The vehicle group also demonstrated a significant decrease in
positive responses at day 60 compared to day 14 (p=0.002), the positive responses were
still 50% greater than the baseline. No significant decreases in positive responses were
demonstrated with the 26-gram force in the gabapentin-treated animals.
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Figure 8: Hyperalgesia above the level of injury: There was a significant increase in
positive responses in the SCI animals after injury at day 14. Only the minocycline group
had significantly decreased responses with treatment that remained through day 60.
Error bars display the mean ± SEM. [(*) p<0.004 vs. baseline; (†) p <0.007 vs. naïve;
(#) p <0.006 vs. day 14/28]

Positive responses increased at day 14 and day 28 in all injured animals compared to
baseline with application of the 26-gram force von Frey filament below the level of injury
(Figure 9). However, only the vehicle and gabapentin treatment groups demonstrated
significantly increased positive responses at day 14 and day 28 compared to baseline
(p<0.004). After two weeks of treatment with minocycline (day 42), positive responses did
not significantly increase. The vehicle group did not show a significant decrease in response
at any testing session. However, two weeks of gabapentin treatment significantly reduced
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positive responses at day 60, 10 days after treatment was complete (washout period) when
compared to day 14, day 28 and day 42 testing sessions (p<0.009).
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Figure 9 Hyperalgesia below the level of injury: There was no significant increase in
response in the minocycline group and no significant change after treatment. The vehicle
and gabapentin groups demonstrated significantly increased responses to the 26-gram
force after injury at day 14 and day 28. The gabapentin group had a significant decrease
in positive responses at day 60. Error bars display the mean ± SEM. [(*) p<0.004 vs.
baseline; (#) p <0.009 vs. day 14/28]

C. Photobeam Activity Box
Animals were placed in a photobeam activity box for a total of 15 minutes during
each behavior testing session. The activity box measured a series of locomotor behaviors
in a software database for analysis of overall activity and fine and gross motor
movements.
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The distance that the animals moved throughout the chamber in 15 minutes was
recorded in total centimeters. The naïve animals did not demonstrate any significant
changes at any time point. However, all injured animals displayed significantly
decreased distance in the chamber at day 14 (p<0.002, Figure 10). At day 28, the vehicle
and minocycline-treated animals continued to show a significant decrease in total
distance (p<0.002), while the gabapentin-treated animals did not demonstrate a
significant decrease in total distance compared to baseline. Post-treatment (day 42 and
day 60) minocycline did not increase total distance moved while gabapentin significantly
increased at day 42 and day 60 compared to day 14 (p<0.005). However, the difference
in total distance moved at day 42 and day 60 in the gabapentin group was not
significantly different compared to day 28. The vehicle group demonstrated a significant
increase in total distance moved at day 60 compared to day 14 (p=0.004), however it
was also not significantly different when compared to day 28.
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Figure 10 Total Distance: There was not a significant increase in total distance in the
minocycline group post-treatment. The gabapentin and vehicle group significantly
increased total distance at day 60 compared to day 14. Error bars display the mean ±
SEM. [(*) p<0.002 vs. baseline; (†) p <0.007 vs. naïve; (#) p <0.005 vs. day 14/28]
The average speed (cm/sec) the animals traveled in the activity box chamber was
recorded throughout the 15 minutes. All injured animal groups significantly reduced their
average speed by day 14 (p<0.004; Figure 11). At day 28, all the injured animals showed a
reduction in average speed. However, the vehicle and minocycline treatment groups were
the only groups that demonstrated a significant decrease in average speed compared to
baseline (p<0.001). At day 42, two weeks post-treatment, the vehicle and minocycline
groups still demonstrate a significant decrease in average speed compared to baseline
(p<0.004). At day 60, ten days after the dosing regimen ended, all injured animal groups

[36]

significantly increased in average speed compared to day 14 (p<0.003). The average speed
of the naïve group was consistent over time and had no significant changes.
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Figure 11 Total Average Speed: All injured animals had significantly reduced average
speeds after injury and all groups significantly improved their speeds by day 60. Error
bars display the mean ± SEM. [(*) p<0.004 vs. baseline; (†) p <0.005 vs. naïve; (#) p
<0.003 vs. day 14/28]
During the 15 minutes that the animals were in the activity box chamber, the software
calculated the total amount of time the animals were at rest in seconds. The amount of time
that each animal was active was then calculated. The naïve animal group displayed no
significant changes throughout each of the testing sessions. All injured animal treatment
groups were significantly less active at day 28 (p<0.002; Figure 12). By day 60, all injured
animal treatment groups were significantly more active when compared to day 28
(p<0.003).
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Figure 12 Total Active Time: All injured animals displayed a significantly decreased
amount of time spent active post-injury at day 28. At day 60, ten days after treatment was
stopped, all injured animals significantly increased their time spent in an active state
compared to day 28. Error bars display the mean ± SEM. [(*) p<0.002 vs. baseline; (†) p
<0.005 vs. naïve; (#) p <0.003 vs. day 14/28]

The PAS software calculated the total amount of ambulatory movements or total gait
made by each animal within the 15 minutes. The naïve un-injured animals displayed
consistent gait at each testing session and no significant changes were found, as expected.
After injury, all SCI animal groups significantly decreased the total amount of ambulatory
movements at day 14 and day 28 (p<0.002; Figure 13). After treatment (day 42 and day 60),
there were no significant improvements in the amount of ambulatory movements made by
any treatment group.
[38]
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Figure 13: Total Ambulatory Movement: All injured animals had significantly reduced
ambulatory movement after injury at day 14 and day 28. There were no significant
improvements in any SCI animal group post-treatment. Error bars display the mean ± SEM.
[(*) p<0.002 vs. baseline; (†) p <0.003 vs. naïve]

The PAS software calculated the total amount of rearing events or amount of times
the animals stood on their hind limbs. The naïve un-injured animals had a significantly
decreased amount of rearing events at day 28, 42 and 60 (p<0.005; Figure 14). All injured
animal groups displayed a significantly decreased amount of rearing events after injury at
day 14 and day 28 (p<0.005). The minocycline group maintained a significantly reduced
amount of rearing events throughout day 60 (p<0.005). At day 42, after 2 weeks of
treatment, the gabapentin group significantly increased the total amount of rearing events
compared to day 14 (p<0.001). At day 60, ten days after gabapentin treatment was complete
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(washout period), the total number of rearing events remained significantly higher compared
to day 14 (p<0.001).
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Figure 14 Total Rearing Events: A significant decrease in rearing events occurred after
injury in all SCI animal groups at day 14 and 28. There was no significant improvement
in the vehicle and minocycline group post-treatment. Gabapentin significantly increased
the total number of rearing events at day 42 and day 60. Error bars display the mean ±
SEM. [(*) p<0.002 vs. baseline; (†) p =0.001 vs. naïve; (#) p =0.001 vs. day 14
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Adverse Side Effects
The original study paradigm included a 4-week dosing regimen of 50 mg/kg via i.p.
injections of minocycline. However, minocycline produced concerns approximately two
weeks after treatment began. Minocycline treatment via i.p. administration began producing
sores around the injection sites even with sufficient rotation of appropriate injection sites in
the left, right and center abdominal areas. There were no visible sores in the vehicle-treated
animals receiving daily i.p. injections of 3 mL of saline. Therefore, I decided to conclude
treatment of minocycline after three weeks of administration instead of the full 4 weeks as
laid out in our original study paradigm. This resulted in the development of aim 2 of this
study, using the ten day washout period before day 60 testing to determine if any lasting
effects at reducing pain were maintained.
The body weights of all treated animals were monitored throughout the dosing regimen.
The minocycline-treated animals displayed abnormally low weight gain when compared
with the gabapentin and vehicle-treated animals (Figure 15). By the end of the 3rd week of
daily dosing the gabapentin-treated animals had gained an average of 23 grams compared to
their weight at the end of week one dosing and the vehicle group had gained an average of
16 grams. However, the minocycline-treated animals had only gained an average of 2 grams
over the same time period.
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Figure 15 Average weight gain After 3 weeks of monitoring weight and daily dosing,
minocycline treatment caused abnormally low weight gain (average= +2 grams) compared
to the saline treatment (average= +16 grams) and the gabapentin treatment (average=+23
grams).
After completion of all behavioral assessments, the animals were sacrificed and a transcardial perfusion was properly performed using buffered-saline with heparin followed by
4% paraformaldehyde. During this procedure, I noticed a remarkable difference in the livers
of the minocyline-treated animals compared to the gabapentin and saline-treated animals
(Figure 16A, 16B and 16C). Therefore, the livers were collected (n=1, per treatment group)
and properly stored. Histology and immunohistochemistry techniques were performed for
analysis.
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Figure 16: (A) Gross anatomy of a vehicle treated animal liver; (B) Gross anatomy of a
gabapentin treated animal liver; (C) Gross anatomy of a minocycline treated animal liver
displaying an obvious increase in fibrous tissue.
Because of the obvious increase in fibrous tissue on the exterior surface of the
minocycline treated animal liver, 30 µm sections of the liver were cut on a cryostat for
subsequent staining procedures. To determine if minocycline caused liver damage I first
performed a hematoxylin and eosin (H & E) stain. Hematoxylin stained the nuclei blue, and
eosin stained the cytoplasm and extracellular proteins pink (Figure 17A, 17B, 17C). The
livers of the saline and gabapentin-treated animals appear to have equally spaced cellular
structure whereas the liver of the minocycline-treated animal appears to have abnormally
increased cellular density and thickening near the exterior surface in the upper right quadrant
of the tissue section.
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Figure 17: 4x image of H&E stain (A) saline-treated animal liver; (B) gabapentin-treated
anima liver; (C) minocycline-treated animal displaying increased cellular density and
thickness toward the exterior surface in the upper right quadrant. Scale bars= 500µm

In order to gain a better understanding of what was developing in the minocyclinetreated rat liver, I decided to stain sections with a trichrome stain. The trichrome stain
provides more detail of structures by staining nuclei black, staining cytoplasm of
hepatocytes red and staining collagen and mucin bright blue. The extent of liver fibrosis in
patients can usually be determined after a biopsy with a trichrome stain coupled with H&E
stain (86). The results of the trichrome stain indicate there is a massive amount of collagen
on the exterior surface of the liver in the minocycline-treated animal (Figure 18C). The
collagen, indicated in blue, also appears to be infiltrating deep into the liver tissue. There
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was no abnormal collagen expression found on the exterior of the liver in the saline and
gabapentin-treated animals (Figure 18A and 18B).
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Figure 18: 4x image of Trichrome stain (A) saline-treated liver; (B) gabapentin-treated
liver; (C) minocycline-treated liver displaying large collagen deposits on the exterior
surface and infiltrating into the tissue. Scale bar=500µm
The minocycline-treated animal liver showed obvious signs of health problems
characterized by abnormally low weight gain during treatment and liver fibrosis. In order to
determine if minocycline caused inflammation in the liver I decided to perform
immunohistochemistry with a known pro-inflammatory cytokine, Interleukin 1-beta (IL1-β).
During acute and chronic stages of inflammatory response caused by many types of injury
and disease, monocyctes and macrophages release IL1-β (87). The results of the IL1-β
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immuno-fluorescence labeling indicated that there was no IL1-β expression found in the
saline and gabapentin-treated animal livers (Figure 19A and 19B). However, I identified a
substantial up-regulation of IL1-β expression that was widespread in the minocycline-treated
animal liver section visible by labeling with bright green fluorescence in Figure 19C.
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Figure 19: 10x image of immuno-labeling with pro-inflammatory cytokine, IL1β (A) salinetreated animal liver; (B) gabapentin-treated animal liver; (C) minocycline-treated animal
liver displaying substantial expression of IL1-β. Scale bar=250 µm
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In order to determine if the positively labeled IL1-β cells in the minocycline-treated
animal liver infiltrated due to an inflammatory response or simply resident cells, I decided to
label the tissue with markers for IL1-β and ED-1. ED-1 is a marker of activated
macrophages. Macrophages are known to migrate to sites of inflammation where they
activate and release a host of cytokines and toxic radicals to remove debris and kill invading
pathogens (88). IL1-β expression co-labeled with ED-1 would further explain that
minocycline caused an infiltrating, inflammatory response leading to hepatoxicity. The
results indicated that IL1-β was highly co-localized with ED-1 in the minocycline-treated
animal liver (Figure 20).

Figure 20: 20x image immuno-label using ED-1, a marker of activated macrophages, in
liver of minocycline-treated animals. ED-1 (red) is highly co-localized with immunolabeling of IL1-β a pro-inflammatory cytokine in green. Scale bar=100 µm
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DISCUSSION
The purpose of this study was to investigate the potential therapeutic benefit of longterm minocycline administration to attenuate or abolish established CNP after SCI. I
performed a series of pre-clinical pain behavior assessments in a rodent model of SCI. First,
I focused on determining if a two week dosing regimen of minocycline (50mg/kg) could
attenuate established CNP. I then determined if a ten day washout period of the drug would
reduce CNP long-term. Finally, I compared the efficacy and safety of minocycline with the
current “gold standard” of treatment, gabapentin. I hypothesized that long-term
administration would decrease established CNP following a severe contusion SCI in a
rodent model.
Minocycline
I found that systemic minocycline treatment attenuated established neuropathic pain in
rats following spinal cord injury. This treatment is in accordance with the precedent set by
several pre-clinical studies that showed an attenuation of SCI-induced pain with acute
treatment of minocycline administered shortly after injury (46),(65),(66),(67),(62),(28),(39).
Previous studies have focused on early intervention for neuropathic pain after SCI with
minocycline treatment administered shortly after the SCI. While the ability to suppress CNP
before it can become established will provide hope to those who encounter an SCI in the
future, it should be noted that there are many individuals living in the chronic phase of SCI
and approximately 65% have established CNP (89).
This study focused on finding a therapeutic intervention for reducing or stopping
neuropathic pain long after establishment. The study focused on providing knowledge that
could potentially benefit thousands of individuals who are enduring CNP many years after a
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traumatic SCI event. A pre-clinical SCI study by Hains and Waxman showed that a brief,
three day treatment regimen with minocycline could attenuate established neuropathic pain
in rats 30 days post-SCI. However, the pain returned immediately after treatment was
stopped (36). This study is the first to show that it was possible to reduce established CNP
via long-term administration of minocycline in both below-level mechanical allodynia of the
hind paws and hyperalgesia above the level of injury.
I observed no significant reduction in below-level hyperalgesia after two weeks of
minocycline treatment. The animals may have experienced pain on the torso area below the
level of injury. However, an alternative explanation is that pain levels remained high due to
application of a noxious force near the sites of irritation caused by i.p. injections.
I also observed that there were no significant improvements in exploratory behavior such
as distance, speed and active time after two weeks of minocycline administration.
Spontaneous, exploratory behavior can be used to measure pain-like behaviors in an
indirect, non-evoked manner because animals in pain move less (84). Measuring pain in
animals is a difficult task not only because of the complexities of CNP development, but
also because of the inability to define pain in animal subjects that correlates to all the pain
modalities experienced by SCI patients. The photobeam activity box software may help us
to identify symptoms of non-evoked pain or pain where no peripheral stimulus exists. Nonevoked pain is a major contributor of severe CNP in humans (89),(90),(91).
After injury, the animal subjects displayed a significant decrease in spontaneous
behavior such as distance, average speed, active time, ambulatory movement and rearing.
Therefore, any significant improvements in spontaneous behavior after treatment could be
associated with a decrease in overall pain. The minocycline treatment group followed the
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same trend as the vehicle treatment group when comparing distance moved, average speed
moved and amount of time spent active over time. I found a significant decrease in
ambulatory movement and rearing events compared to the baseline that also followed the
same trend of the vehicle treatment group. This data suggests that overall pain may still have
affected the minocycline and vehicle-treated animals post-treatment.
The lack of improvement in exploratory behavior after two weeks of minocycline
treatment could be due to gut irritation from repeated i.p. injections and possible toxicity
problems as previously described. The sores caused a great restriction in hind limb motor
movement that did not allow the animal to have proper locomotor function while on the
dosing regimen. It was unclear whether the observations were due to a continuing
phenomenon of CNP, from irritation of the i.p. injections or from toxicity due to the
treatment schedule. In future studies with long-term minocycline administration it will be
important to use a different mode of administration and an alternative schedule for long-term
dosing to rule out issues caused by i.p. injection and toxicity.
Despite the discrepancy in the activity box data most of the suppressed behavioral trends
while on the minocycline dosing regimen improved by day 60 testing. The sores caused by
repeated i.p. injection healed after the ten day washout period of the drug and the trends in
distance, speed, active time, ambulatory movement and rearing events improved compared
to day 42. This suggested that the animals may have recovered a portion of their locomotor
function that was previously restricted due to the i.p. injections. It was also possible that the
animals were experiencing less pain because the wounds were healed. However, due to
improving trends in all of the same behavior assessments in the vehicle treatment group, this
remained unclear. Overall improvements in locomotor function and behavior activity in the

[50]

vehicle treatment group suggested that there was an obvious, naturally occurring
improvement in the Sprague-Dawley rat model of SCI, 60 days post-injury.
This study was the first to discover that minocycline had a lasting effect in reducing
CNP after SCI. I found that even after the ten day washout period of minocycline, belowlevel mechanical allodynia and above-level hyperalgesia significantly diminished. The halflife of minocycline in rodents is approximately two to three hours which means the drug is
completely out of their system by day 60 testing following a final dose at day 50 (92). I
found that minocycline produced a sustained reduction in CNP, and this contradicts
previous findings by Hains and Waxman who showed that pain returned immediately
following withdrawal of minocycline (36). Hains and Waxman tested minocycline with a
three day regimen of twice daily injections (100 ug/5 ul) intrathecally while I administered
minocycline a total of three weeks intraperitoneally (36). The two different modes of
administration vary greatly. An intrathecal dose involves an intrathecal catheter placed in the
lumbar enlargement of the animal subject and correlates to an intrathecal injection in
humans where a drug can be delivered into the fluid cavity surrounding the spinal cord (93).
This method has the disadvantage of being an extremely invasive procedure. However, the
intrathecal delivery method eliminates the concern that the drug will not pass the bloodbrain-barrier by making the injection directly into the spinal cord. For example, SCI patients
received continuous administration of baclofen, a drug that specifically targets Gammaaminobutyric acid (GABA) receptors within the spinal cord, by an implanted intrathecal
pump (94). This method was not only safe; it was significantly more effective than an oral
dose and required a dose amount that was 100-fold less than an oral dose (94).
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Intraperitoneal injections place the potential therapeutic directly into the intraperitoneal
space in the lower abdominal area with caution to avoid contacting any organs. The
advantage of i.p. administration is that it is the most widely used method in rodents for safe,
systemic delivery of drugs (95). However, it does not correlate well to humans. Currently,
clinicians are only using intraperitoneal injections for delivery of several chemotherapy
agents(96). However, they are highly controversial because of the risk of complications and
toxicity (96). Overall, the differences in the mode of administration in animal subjects can
vary greatly and can cause differences in outcome, efficacy and side effects. It is most
important to deliver the drug in a safe and tolerable manner in the animal subjects to ensure
that the drug is able to target the intended mechanisms of action effectively.
The possible mechanisms by which minocycline administration could attenuate CNP is
still unclear, however there are several interesting CNP mechanisms that it may target. A
robust immune response followed by inflammation of the tissue surrounding the injury is a
prolonged pathological event after SCI that contributes to CNP (42),(21). Minocycline is
considered a multi-target or “dirty” drug because aside from antibiotic properties, it also
targets the inflammatory response through the inhibition of microglia activity (36),(39),(97)
(98). Microglia cells within the spinal cord normally remain in an inactive/resting state to
maintain architecture and homeostasis of neuronal cells (41). After SCI, microglia cells
activate, display “ramified branches” and release pro-inflammatory cytokines (41),(36).
Fleming-Norenberg et al. reported that activated microglia were abundant up to one-year
post-SCI in humans (20). Activated microglia cells produce an ongoing inflammatory
response that correlates with maintenance of CNP (42),(43),(36),(44). Inhibition of
microglia activation by minocycline administration reduces the production of pro-
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inflammatory cytokines such as TNF-α, IL-β, IL-6 and prostaglandin-E2 (PGE2) that
contribute to the continuation of pain (98). Minocycline inhibits matrix metalloproteinases
(MMPs) activity, which reduces inflammation and prevents tissue remodeling (60). After
SCI, MMPs become activated; exhibiting enzymatic activity that breaks down extracellular
matrix components. While a crucial activity for permitting angiogenesis, MMP activation
also contributes to inflammation and tissue damage within the spinal cord (60). Minocycline
also inhibits apoptosis by inhibiting cytochrome c release from the mitochondria, an initial
step in the signaling of the apoptosis cascade (61),(62). Inhibition of apoptosis prevents cell
death, spares tissue around the spinal cord and contributes to an overall neuroprotective
environment (67),(62),(66),(65).
Due to minocycline’s ability to target the immune response, I must also be aware that
the wounds from repeated i.p. injections may have been prevented from healing. The
wounds depend upon the immune system’s ability to heal efficiently. However, minocycline
may inhibit the immune cells necessary for wound healing which, in this model, may have
delayed the healing process. Overall, the finding suggested that long-term i.p. administration
of minocycline at 50 mg/kg had a lasting effect of reducing some symptoms of CNP after
SCI. While this study is not mechanistic in nature, I am intrigued by the possibility that
sustained minocycline treatment may exert a sustained reduction in pain through modulation
of known inflammatory mechanisms. This question will be addressed in subsequent studies.
Minocycline vs. Gabapentin
Gabapentin (Neurontin ®) is the current “gold standard” drug prescribed for the
treatment of CNP in chronic SCI patients. The use of gabapentin includes multiple adverse
side effects that include dizziness, somnolence and nausea (52). It has been well-established
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that gabapentin has the ability to transiently reduce symptoms of CNP (99). Yet many
clinicians are seeking alternatives to gabapentin due to adverse side effects. Patients who use
gabapentin as a treatment for CNP often complain that it provides inadequate pain relief and
also causes a multitude of adverse side-effects that make it difficult to function in daily life
(53),(52). In order to determine the potential of minocycline to replace gabapentin as a
standard of treatment for CNP I focused on comparing the efficacy and safety of both drugs.
The results indicated that gabapentin reduced below-level mechanical allodynia after
two weeks of daily dosing with 50 mg/kg via subcutaneous injections. This concentration of
gabapentin was chosen based on a previous study by Hama and Sagen who found that 50
mg/kg effectively reduced CNP after SCI in a rodent model (75). Minocycline is equally as
effective at reducing below-level allodynia at this time point, which provided further
evidence that minocycline could be a potential new therapeutic intervention for CNP.
Gabapentin treatment reduced below-level mechanical allodynia at day 60 testing, ten
days after withdrawal of gabapentin. The data suggested that the reduction in pain was longterm because the effects were still significant ten days after gabapentin treatment ceased.
Gabapentin has a very short half-life in rodents of 1.7 hours (100). Therefore, I expected
pain levels to return by day 60 testing.
I observed no reduction in above-level hyperalgesia in the gabapentin treatment group
using the girdle response test. This is in contrast to my finding that minocycline treatment
significantly reduced pain at this level. The data suggested minocycline may effectively
reduce symptoms of hyperalgesic pain above the level of injury that gabapentin cannot and
that there may be different mechanisms responsible for above level pain compared to below
level pain which should be further explored.
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Gabapentin treatment significantly diminished below-level hyperalgesic pain whereas
minocycline treatment did not. Interestingly, the reduction of pain was observed during day
60 testing, ten days after dosing was complete. I did not expect to see a significant decrease
in below-level hyperalgesia after a ten day washout period because of gabapentin’s short
half-life. Therefore, long-term gabapentin treatment may have a lasting effect at reducing
below-level hyperalgesia in a rodent model of SCI.
I found a significant increase in pain at day 42, while the animals were on the dosing
regimen of gabapentin. The significant increase in below-level hyperalgesia could be
explained by the mode of administration. Subcutaneous injections were made in the same
areas where the application of the filaments was placed on the torso. Therefore, the
significant increase in pain at day 42 could be explained by hypersensitivity caused by the
mode of administration causing pain or irritation on the animal’s lower torso area. This may
also explain why there was no reduction in above-level hyperalgesic pain using the girdle
response test after gabapentin treatment. The results suggested that gabapentin may have
had a lasting effect at reducing below-level hyperalgesia and below-level allodynia. The data
is in contradiction to the current literature that demonstrates that neuropathic pain levels
return shortly after withdrawal of gabapentin treatment in a rodent model of SCI (101).
In addition to the unexpected findings after the washout period, I also observed a lasting
improvement in the behavioral activity data. Total distance significantly increased at day 42
and day 60 in the gabapentin treatment group whereas the minocycline group continued to
decrease. The vehicle treatment group also significantly increased total distance at day 60
indicating that the natural improvement over time most likely accounted for the
improvements with total distance, average speed and active time.
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Interestingly, gabapentin treatment significantly improved the number of rearing events
within the activity box over the 15 minute period. I did not observe this in any other
treatment group. Gabapentin-treated animals demonstrated a significant increase of rearing
events at day 42 and after the ten day washout period at day 60. This is the first study to
show that long-term gabapentin treatment could increase the number of rearing events after
an extended washout period in a rodent model of SCI. This suggested that gabapentin
provided long-lasting relief at reducing below-level pain, which allowed the animals to feel
more comfortable standing up on their hind limbs. However, the increase in rearing events
could also indicate that the animals had more homeostatic control over their muscles and
therefore, improved trunk stability. It could also mean that perhaps gabapentin treatment
reduced secondary injury and improved motor function recovery after SCI in the animal
model.
Gabapentin treatment may improve trunk stability or provide neuroprotection and
prevent secondary injury by an unknown mechanism. Recently, a single dose of gabapentin
(200mg/kg or 30mg/kg) administistered immediately after injury in a rabbit model of spinal
cord ischemic injury significantly protected the ultrastructure of the spinal cord (102). This
study suggested that a single dose of gabapentin immediately after ischemic injury could
have neuroprotective effects. Likewise, a pre-clinial study demonstrated that a single dose
of gabapentin (200mg/kg or 30mg/kg) in a rat model of SCI demonstrated significant
neuroprotective characteristics by examination of spinal cord tissue and plasma levels (103).
Perhaps long-term gabapentin treatment was administered at an oportunistic time window
post-injury in my study that provided neuroprotective effects and reduced secondary injury
and increased motor recovery of the hind limbs.
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Additionally, a recent study also demonstrated that gabapentin significantly reduced
symptoms of muscle spasticity and autonomic dysreflexia with a single dose of gabapentin
(50 mg/kg, i.p.) in an SCI rodent model when measured between 2 and 3 weeks after injury
(12). Autonomic dysreflexia is a severe and painful condition characterized by a rapid attack
that causes an enormous increase in blood pressure, shivering, sweating, anxiety and severe
headaches (13).
Muscle spasticity and intense, painful muscle spasms are common complaints among
SCI patients (12). Abnormal somatic and autonomic motor reflexes are thought to be the
cause of symptoms associated with muscle spasticity and autonomic dysreflexia after SCI
(12). In 1997, Gruenthal et al. performed a clinical trial to test if (2,400 mg over 48 hours)
gabapentin treatment could reduce muscle spasticity in SCI patients. The authors concluded
that gabapentin treatment significantly decreased muscle spasticity, which consequently
improved the patients’ overall quality of life (104). Gabapentin may diminish the somatic
and autonomic motor reflex pathways by inhibiting glutamate release at presynaptic
terminals in neurons (12). In my model of SCI, long-term gabapentin treatment may have
produced similar effects. By reducing muscle spasticity with gabapentin treatment, this
could explain why the animals had an increase in rearing events and perhaps long-term
gabapentin treatment could contribute to more homeostatic control of muscles or increased
muscle tone.
The currently accepted mechanism of gabapentin is its ability to binds to a calcium
channel subunit, alpha-2-delta, and reduce calcium influx into cells (49),(50),(51). This
decreases excitability of neurons (49),(50),(51). Decreasing the excitability of neurons by
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inhibiting transmitters such as glutamate and substance-P provides an analgesic effect
(50),(51). However, I propose that gabapentin treatment and its mechanisms of action should
be further investigated for its potential as an early intervention after SCI to prevent or reduce
symptoms that develop into chronic conditions such as neuropathic pain, muscle spasticity
and autonomic dysreflexia. Taking into account all of the unexpected improvements
demonstrated after the washout period and the significant increase in rearing events, not
only does long-term gabapentin-treatment reduce pain; it may also beneficially target
additional mechanisms that lead to permanent changes and muscle tone and recovery after
injury.
Additionally, I measured pain by application of von Frey hair filaments. However, I
cannot rule out the possibility that an intense flinch reaction above or below the level of
injury using the girdle test may instead be an intense reflex reaction in our animal model.
Likewise, I cannot rule out the possibility that a quick withdrawal of the hind paw using the
von Frey hair test may instead be an intense reflex reaction. Provoking a reflex reaction
instead of pain would indicate the animals are experiencing increased muscle spasticity and
application of filaments on the hind limb and hind paw were simply inducing a severe
muscle spasm. Recent studies suggest that this may be the case when measuring
hypersensitivity below the level of SCI. Baastrup et al. reported that when measuring belowlevel pain in a rat model of SCI there was no indication of an increase in brainstem reflexes
or unpleasant behavior which would be indicative of pain development as it correlates to
humans (105). They concluded that they were simply measuring spinal reflexes and that
measuring spinal reflexes is most likely not an appropriate measure for studying below-level
pain development in rodents (105). Likewise, Urban et al. reported in a recent pre-clinical
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study on mice that measuring mechanical hypersensitivity may not adequately measure
chronic pain because they did not find any significant behavior changes such as increased
anxiety, depression or changes by examining home cage behaviors which would indicate a
decrease in quality of life compared to control animals (106). They indicate that depression
and an alteration in daily activities in human patients living with chronic pain is a relevant
and critical feature of chronic pain and that the mice did not develop these qualities which
would indicate chronic pain development (106).
Therefore, my data could also suggest that gabapentin and minocycline may
specifically target mechanisms underlying muscle spasticity and motor recovery after SCI
instead of pain. Several studies indicate that acute minocycline treatment improves hind
limb motor recovery weeks after injury using the BBB test and that minocycline has a
neuroprotective effect after injury (66), (62),(67),(65). Therefore, minocycline could also
improve motor recovery and decrease muscle spasticity with long-term administration and
needs to be explored with additional, more rigorous assessments of motor function in
subsequent studies.
Adverse Side Effects
I found several unexpected, negative side effects caused by a three week daily dosing
regimen of 50 mg/kg minocycline administration via i.p. injections. The minocycline
treatment group demonstrated abnormally low weight gain when compared with the other
treatment or vehicle groups. Because this was the first assessment of a delayed, long-term
dosing regimen of minocycline in an early chronic rat model of SCI, the toxicity levels were
uncertain. One explanation for the low weight gain could be due to the antibiotic properties
of minocycline. However, it is unclear whether antibiotics such as minocycline can cause
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decreased appetite. In contradiction to our findings recent evidence suggests that extensive
use of antibiotics including minocycline, may actually cause weight gain in patients (107).
Therefore, the abnormally low weight gain in the minocycline treatment group could be
indicative of signs of toxicity. I must consider that the dosing-schedule, concentration (50
mg/kg) and/or mode of administration (i.p.) were the cause. A wide range of pre-clinical
studies of CNS trauma and disease have used concentrations of minocycline ranging from
10-100 mg/kg (28),(62),(67),(66),(65),(46). However, pre-clinical studies in rats using the
i.p. delivery route have shown efficacy in improving functional recovery and attenuating
pain with only acute treatment of minocycline. These acute studies range from a single dose
to a maximum 5 day dosing regimen with concentrations ranging from 45 mg/kg to 180
mg/kg (28),(62),(67),(66),(65),(46). This was the first study to show complications of longterm minocycline administration via i.p. injections in a Sprague-Dawley rat model of SCI.
In addition to abnormally low weight gain, long-term i.p. injections caused extensive
chemical burns and sores around the sites of injection in the abdominal area. This is
consistent with the findings by Nessler et al. who discussed a concern that the effects of
minocycline treatment causing abdominal irritation with repeated dosing of 100 mg/ml i.p.
injections in a rat model of autoimmune encephalomyelitis (108). Additional research would
be advantageous for understanding the proper mode of administration and correct
concentration of minocycline in a rat model of SCI as an important step to assess efficacy
prior to clinical translation. A pre-clinical assessment utilizing several modes of
administration such as intrathecal, oral gavage and intravenous would provide further
evidence as to which method is the most efficacious in the SCI rat model. Discovering the
proper mode of administration in animal subjects is critical for effective translation into
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clinical trials. Intraperitoneal injections (i.p.) have little relevance to translation in humans
except for chemotherapy delivery, whereas intrathecal, oral gavage and intravenous
injections are not only relevant, they can help determine the safest and most effective
delivery method for patients. In addition, I further recommend performing a pre-clinical
dose-response test to determine the optimal dose of minocycline that would effectively
decrease CNP and minimize the negative side effects. Finally, my data suggested that a
reduction in pain may be possible beyond the cessation of treatment. If this is the case, it
will be important to determine the shortest possible time period for delivery of minocycline
to elicit a long-term reduction in CNP while preventing or minimizing the adverse side
effects observed with long-term minocycline treatment.
I observed a pronounced cellular inflammatory response in the livers of minocyclinetreated subjects that suggested the onset of minocycline treatment-dependent hepatoxicity.
Hepatoxicity is defined as drug-induced liver injury and is often difficult to diagnose in
patients (109). My observations indicated that hepatoxicity may have occurred in the
minocycline-treated subjects. This may have been due to the observed increase in collagen
production as well as the presence of macrophages, many of which co-localize with the proinflammatory cytokine, IL1-β. There are several reports of hepatotoxicity in pre-clinical SCI
studies using minocycline. It is unclear if the liver damage observed in my study was due to
long-term administration or because of the route of minocycline administration. Some
damage to the liver could be due to the close proximity of the liver to the area in which the
drug was administered. Minocycline is a drug soluble in a weak acidic solution (pH 5) that
may have affected not only the abdominal epidermis but also organs near the injection sites
(92). Interestingly, my results are in agreement with many human case studies that found
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evidence of liver damage with long-term use of minocycline. This suggests that the liver
damage I observed may not have been caused by i.p. injections alone. Autoimmune hepatitis
and liver damage from tetracycline antibiotics such as minocycline are reported in patients
after an average use of two years (69),(68). Additionally, SCI patients could be predisposed
to autoimmune hepatitis or liver disease due to their injury alone and minocycline could
greatly increase their chances of developing hepatoxicity. Researchers and clinicians are
discovering that SCI may cause decreased metabolic function, or function of the liver, due to
recent evidence found in pre-clinical models of SCI and in patients with SCI (110),(111).
Research studies focusing on the degree of metabolic dysfunction and drug-induced liver
damage in a rodent model of SCI would be very helpful in determining a patient’s benefitrisk ratio of taking drugs known to cause hepatoxicity. In future studies it will also be
important to identify the minimal dose of minocycline required to reduce pain long term
while also minimizing toxicity.

Limitations
The study of pain in animals is very difficult because pain is a highly subjective
sensory interpretation. The tests developed and used in my study to measure pain were
developed based on the assumption that the stimulus applied to an animal will evoke pain
much like it does in humans. I measured mechanical hypersensitivity of the hind paws with
the use of von Frey filaments with increasing force which correlated to peripherally-evoked
mechanical allodynia in humans. I measured hypersensitivity of the torso using the girdle
test which correlates to peripherally-evoked hyperalgesia and allodynia of the torso in
humans. Finally, I measured spontaneous behavioral activity of the animal subjects to
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perhaps provide better insight into the development of non-evoked pain or spontaneous pain
which correlated to the development of spontaneous/non-evoked neuropathic pain in
humans. SCI patients experience spontaneous neuropathic pain with sensations described as
burning and pricking usually at or below the level of injury (90). Phantom pain is
spontaneous pain that does not require a peripheral stimulus and occurs where there is total
sensory loss (90). I also cannot rule out the possibility that the von Frey hair filaments are
simply evoking a reflex response instead of pain as previously described. Determining
whether the pain behavior tests used in rodents acccurately measure pain or instead measure
muscle spasticity would greatly impact the field of study on neuropathic pain.
I did not measure thermal sensitivity of the hind paws in the animal subjects.
Thermal sensitive testing in animal subjects correlates to thermal sensitivity in SCI patients
who often experience a significantly increased response to hot and cold temperatures, most
often above the level of injury (112). I also did not use the Randall-Selitto test which
measures nociceptive withdrawal threshold of the dorsal and plantar surfaces of the paws by
applying an increasing amount of force with an electronic algesimeter until the animal
withdrawals the paw (113). Recently, Santos-Nogueira et al. used the Randall-Selitto test to
measure neuropathic pain in animal models of both spinal cord contusion and transection
injury (114). They found that the test was a sensitive and adequate measure of neuropathic
pain in the animal subjects and that earlier time points could be tested compared to the von
Frey hair test because weight support was not required (112). In future studies, it would be
beneficial to combine behavior testing with developed diagnostic and physiological
measures of pain in animals. The lab of Dr. Raymond Grill is currently developing an
approach to discern evoked verses non-evoked pain using non-invasive functional MRI.
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Based on my results there was high variability in the amount and types of
neuropathic pain each animal experienced that I believe correlated well with studies on
neuropathic pain in humans. Pain prevalence data after SCI is difficult to gather and analyze
due to the many classifications and ways of identifying neuropathic pain in humans (7). In
my study, some animals developed increased sensitivity to the mechanical allodynia test
while other animals only developed sensitivity in the hyperalgesia test. Using several testing
procedures such as von Frey hair test, girdle test and behavior activity can be beneficial in
detecting a wide array of pain symptoms. However, it also makes it difficult to decide which
animals animal subjects to include in the study based on which ones developed significant
levels of CNP. I developed strict criteria to eliminate animals that did not appear to develop
pain after injury, which decreased the total number of animals for analysis. In future studies
that use only behavior tests for outcome measures, it may be useful to develop a strategy to
analyze each test individually, instead of eliminating animals from all tests that did not show
pain in only one or two tests. It may be beneficial to use one behavior test to measure overall
pain and continue to develop better diagnostic strategies for analyzing neuropathic pain in
rodent models.
The animals are extremely sensitive to the testing environment. It was important to
test animals in a quiet room with no other animals or people allowed in and to clean the
testing equipment between each testing session. I moved the location of behavior testing in
the middle of our study and upgraded the von Frey hair testing apparatus. I did not notice
any significant differences in behavior due to these changes.
Additionally, I observed hyper-sensitization in the naïve un-injured group. Animals
are known to produce a “fear scent” if they are in pain, startled or afraid which could cause
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other animals to become stressed (85). The naïve animals may have detected a fear scent
released by the injured animals due to pain and distress from their injuries. In future studies,
it would be beneficial to test the naïve un-injured animals separately from the injured
animals to prevent hypersensitivity in the naïve group.
The girdle test was used to measure sensitivity of the torso area. However, the
animals were rapidly growing in length and girth over the course of the study and changes in
the size of the restraint devices were made over time. This made it difficult to apply the von
Frey filaments in a consistent location at each testing session. Additionally, some animals
became noticeably anxious even after being allowed to acclimate to the device before each
testing session. Therefore, some animals may have flinched or vocalized due to the stress
and anxiety of being secured in a small restraint device instead of actually experiencing
provoked neuropathic pain or muscle spasms.
This was not a completely blind study. I divided the animals into treatment groups at
day 29, which means that baseline, day 14 and day 28 testing were blind and day 42 and day
60 were not. After dosing, animals were divided into treatment groups, and behavior testing
and dosing was performed by one person. It is beneficial to have only one person
performing all behavior tests because some testers will be more stringent than other testers.
In future studies it would be ideal to have two people perform behavior tests and then
average the results of both raters.
Finally, another limitation of this study is that I was only able to look at one
concentration of minocycline for long-term treatment. The dose concentration of 50 mg/kg
used in this study is an average dose commonly used in rodents, as the dosing ranges from
10 mg/kg to 180 mg/kg in most pre-clinical studies of minocycline. The dose concentration
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in humans is approximately 2-3 mg/kg (58). Therefore, minocycline administration is at a
much higher concentration in pre-clinical rodent studies than the common human dose
concentration. This makes translation into clinical trials difficult due to the adverse side
effects I observed with the dosing regimen tested, despite the fact that it is an FDA approved
drug. Perhaps a lower dose of minocycline would be sufficient to reduce pain without
causing liver damage. I suggest further pre-clinical testing with minocycline to develop a
safe mode of administration for long-term use while also performing a dose response test to
identify the minimal dose required to achieve significant pain relief. This is particularly
important in the SCI population as well as other CNS trauma and disease populations that
may be experiencing decreased metabolic function.
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CONCLUSIONS

I have demonstrated that minocycline can attenuate CNP during a long-term dosing
regimen. Further, the anti-nociceptive effects are sustained following cessation of treatment,
suggesting that minocycline may have potential as a clinical therapeutic in the treatment of
SCI-induced CNP.
However, long-term use of minocycline in with the treatment schedule caused
negative side effects such as gut irritation, low weight gain, and hepatotoxicity that need to
be addressed with further pre-clinical studies. Using a lower concentration, different dosage
schedule and different modes of administrations such as oral gavage may reduce the side
effects I observed.
Gabapentin treatment caused a significant and sustained reduction in CNP ten days
after withdrawal of treatment. This result was unexpected because gabapentin has a short
half-life of 1.7 hours in rodents and previous studies have demonstrated that pre-drug pain
levels return shortly after withdrawal of treatment. Additionally, the gabapentin-treated
animals demonstrated a significant and sustained increase in rearing events compared with
all other treatment groups. The data suggested that gabapentin treatment was not only
capable of reducing pain long-term but it may significantly improve trunk stability and
muscle tone or provide neuroprotection which decreased secondary injury.

[67]

REFERENCES

1.

The Christoper and Dana Reeve Foundation Paralysis Resource Center. One Degree
of Separation: Paralysis and Spinal Cord Injury in the United States.

2.

Nesic, O., J. Lee, K. M. Johnson, Z. Ye, G. Y. Xu, G. C. Unabia, T. G. Wood, D. J.
McAdoo, K. N. Westlund, C. E. Hulsebosch, and J. Regino Perez-Polo. 2005.
Transcriptional profiling of spinal cord injury-induced central neuropathic pain. J
Neurochem 95:998-1014.

3.

Tan, A. M., Y. W. Chang, P. Zhao, B. C. Hains, and S. G. Waxman. Rac1-regulated
dendritic spine remodeling contributes to neuropathic pain after peripheral nerve
injury. Exp Neurol 232:222-233.

4.

Bedi, S. S., Q. Yang, R. J. Crook, J. Du, Z. Wu, H. M. Fishman, R. J. Grill, S. M.
Carlton, and E. T. Walters. Chronic spontaneous activity generated in the somata of
primary nociceptors is associated with pain-related behavior after spinal cord injury.
J Neurosci 30:14870-14882.

5.

Hulsebosch, C. E., B. C. Hains, E. D. Crown, and S. M. Carlton. 2009. Mechanisms
of chronic central neuropathic pain after spinal cord injury. Brain Res Rev 60:202213.

6.

Finnerup, N. B., I. L. Johannesen, S. H. Sindrup, F. W. Bach, and T. S. Jensen. 2001.
Pain and dysesthesia in patients with spinal cord injury: A postal survey. Spinal Cord
39:256-262.

[68]

7.

Siddall, P. J., J. M. McClelland, S. B. Rutkowski, and M. J. Cousins. 2003. A
longitudinal study of the prevalence and characteristics of pain in the first 5 years
following spinal cord injury. Pain 103:249-257.

8.

Baastrup, C., T. S. Jensen, and N. B. Finnerup. Pregabalin attenuates place
escape/avoidance behavior in a rat model of spinal cord injury. Brain Res 1370:129135.

9.

Devivo, M. J. Epidemiology of traumatic spinal cord injury: trends and future
implications. Spinal Cord.

10.

Post, M. W., and C. M. van Leeuwen. Psychosocial issues in spinal cord injury: a
review. Spinal Cord.

11.

Roy, R. R., and V. R. Edgerton. Neurobiological perspective of spasticity as occurs
after a spinal cord injury. Exp Neurol.

12.

Rabchevsky, A. G., S. P. Patel, H. Duale, T. S. Lyttle, C. R. O'Dell, and P. H.
Kitzman. Gabapentin for spasticity and autonomic dysreflexia after severe spinal
cord injury. Spinal Cord 49:99-105.

13.

Karlsson, A. K. 1999. Autonomic dysreflexia. Spinal Cord 37:383-391.

14.

Norenberg, M. D., J. Smith, and A. Marcillo. 2004. The pathology of human spinal
cord injury: defining the problems. J Neurotrauma 21:429-440.

15.

Rowland, J. W., G. W. Hawryluk, B. Kwon, and M. G. Fehlings. 2008. Current
status of acute spinal cord injury pathophysiology and emerging therapies: promise
on the horizon. Neurosurg Focus 25:E2.

[69]

16.

Donnelly, D. J., and P. G. Popovich. 2008. Inflammation and its role in
neuroprotection, axonal regeneration and functional recovery after spinal cord injury.
Exp Neurol 209:378-388.

17.

Hausmann, O. N. 2003. Post-traumatic inflammation following spinal cord injury.
Spinal Cord 41:369-378.

18.

Ronsyn, M. W., Berneman, Z. N., Van Tendeloo, V. I., Jorens, P. G., & Ponsaerts, P.
P. August 2008. Schematic presentation of the pathophysiological process of a spinal
cord injury in the acute and the chronic stage with the different treatments options
indicated. In Spinal Cord. 533.

19.

Ankeny, D. P., and P. G. Popovich. 2009. Mechanisms and implications of adaptive
immune responses after traumatic spinal cord injury. Neuroscience 158:1112-1121.

20.

Fleming, J. C., M. D. Norenberg, D. A. Ramsay, G. A. Dekaban, A. E. Marcillo, A.
D. Saenz, M. Pasquale-Styles, W. D. Dietrich, and L. C. Weaver. 2006. The cellular
inflammatory response in human spinal cords after injury. Brain 129:3249-3269.

21.

Popovich, P. G., and T. B. Jones. 2003. Manipulating neuroinflammatory reactions
in the injured spinal cord: back to basics. Trends Pharmacol Sci 24:13-17.

22.

Yan, P., Q. Li, G. M. Kim, J. Xu, C. Y. Hsu, and X. M. Xu. 2001. Cellular
localization of tumor necrosis factor-alpha following acute spinal cord injury in adult
rats. J Neurotrauma 18:563-568.

23.

Sung, B., S. Wang, B. Zhou, G. Lim, L. Yang, Q. Zeng, J. A. Lim, J. D. Wang, J. X.
Kang, and J. Mao. 2007. Altered spinal arachidonic acid turnover after peripheral
nerve injury regulates regional glutamate concentration and neuropathic pain
behaviors in rats. Pain 131:121-131.

[70]

24.

Hains, B. C., J. A. Yucra, and C. E. Hulsebosch. 2001. Reduction of pathological and
behavioral deficits following spinal cord contusion injury with the selective
cyclooxygenase-2 inhibitor NS-398. J Neurotrauma 18:409-423.

25.

McMahon, S. B., W. B. Cafferty, and F. Marchand. 2005. Immune and glial cell
factors as pain mediators and modulators. Exp Neurol 192:444-462.

26.

Samad, T., and S. Abdi. 2001. Cyclooxygenase-2 and antagonists in pain
management. Curr Opin Anaesthesiol 14:527-532.

27.

Yu, W. R., and M. G. Fehlings. Fas/FasL-mediated apoptosis and inflammation are
key features of acute human spinal cord injury: implications for translational, clinical
application. Acta Neuropathol 122:747-761.

28.

Tan, A. M., P. Zhao, S. G. Waxman, and B. C. Hains. 2009. Early microglial
inhibition preemptively mitigates chronic pain development after experimental spinal
cord injury. J Rehabil Res Dev 46:123-133.

29.

Sekhon, L. H., and M. G. Fehlings. 2001. Epidemiology, demographics, and
pathophysiology of acute spinal cord injury. Spine (Phila Pa 1976) 26:S2-12.

30.

de Miguel, M., and D. C. Kraychete. 2009. Pain in patients with spinal cord injury: a
review. Rev Bras Anestesiol 59:350-357.

31.

Hulsebosch, C. E. 2005. From discovery to clinical trials: treatment strategies for
central neuropathic pain after spinal cord injury. Curr Pharm Des 11:1411-1420.

32.

Zhuo, M., G. Wu, and L. J. Wu. Neuronal and microglial mechanisms of neuropathic
pain. Mol Brain 4:31.

33.

Carlton, S. M., J. Du, H. Y. Tan, O. Nesic, G. L. Hargett, A. C. Bopp, A. Yamani, Q.
Lin, W. D. Willis, and C. E. Hulsebosch. 2009. Peripheral and central sensitization in

[71]

remote spinal cord regions contribute to central neuropathic pain after spinal cord
injury. Pain 147:265-276.
34.

Zhuo, M. 2007. A synaptic model for pain: long-term potentiation in the anterior
cingulate cortex. Mol Cells 23:259-271.

35.

Gwak, Y. S., and C. E. Hulsebosch. Neuronal hyperexcitability: a substrate for
central neuropathic pain after spinal cord injury. Curr Pain Headache Rep 15:215222.

36.

Hains, B. C., and S. G. Waxman. 2006. Activated microglia contribute to the
maintenance of chronic pain after spinal cord injury. J Neurosci 26:4308-4317.

37.

Braz, J. M., and A. I. Basbaum. 2009. Triggering genetically-expressed
transneuronal tracers by peripheral axotomy reveals convergent and segregated
sensory neuron-spinal cord connectivity. Neuroscience 163:1220-1232.

38.

Hains, B. C., C. Y. Saab, and S. G. Waxman. 2005. Changes in electrophysiological
properties and sodium channel Nav1.3 expression in thalamic neurons after spinal
cord injury. Brain 128:2359-2371.

39.

Zhao, P., S. G. Waxman, and B. C. Hains. 2007. Modulation of thalamic nociceptive
processing after spinal cord injury through remote activation of thalamic microglia
by cysteine cysteine chemokine ligand 21. J Neurosci 27:8893-8902.

40.

Hubscher, C. H., and R. D. Johnson. 2006. Chronic spinal cord injury induced
changes in the responses of thalamic neurons. Exp Neurol 197:177-188.

41.

Gwak, Y. S., J. Kang, G. C. Unabia, and C. E. Hulsebosch. Spatial and temporal
activation of spinal glial cells: Role of gliopathy in central neuropathic pain
following spinal cord injury in rats. Exp Neurol.

[72]

42.

Detloff, M. R., L. C. Fisher, V. McGaughy, E. E. Longbrake, P. G. Popovich, and D.
M. Basso. 2008. Remote activation of microglia and pro-inflammatory cytokines
predict the onset and severity of below-level neuropathic pain after spinal cord injury
in rats. Exp Neurol 212:337-347.

43.

Sandhir, R., E. Gregory, Y. Y. He, and N. E. Berman. Upregulation of inflammatory
mediators in a model of chronic pain after spinal cord injury. Neurochem Res
36:856-862.

44.

Crown, E. D., Y. S. Gwak, Z. Ye, K. M. Johnson, and C. E. Hulsebosch. 2008.
Activation of p38 MAP kinase is involved in central neuropathic pain following
spinal cord injury. Exp Neurol 213:257-267.

45.

Hulsebosch, C. E. 2008. Gliopathy ensures persistent inflammation and chronic pain
after spinal cord injury. Exp Neurol 214:6-9.

46.

Marchand, F., C. Tsantoulas, D. Singh, J. Grist, A. K. Clark, E. J. Bradbury, and S.
B. McMahon. 2009. Effects of Etanercept and Minocycline in a rat model of spinal
cord injury. Eur J Pain 13:673-681.

47.

Childers, W. E., Jr., and R. B. Baudy. 2007. N-methyl-D-aspartate antagonists and
neuropathic pain: the search for relief. J Med Chem 50:2557-2562.

48.

Sindrup, S. H., and T. S. Jensen. 1999. Efficacy of pharmacological treatments of
neuropathic pain: an update and effect related to mechanism of drug action. Pain
83:389-400.

49.

Gee, N. S., J. P. Brown, V. U. Dissanayake, J. Offord, R. Thurlow, and G. N.
Woodruff. 1996. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the
alpha2delta subunit of a calcium channel. J Biol Chem 271:5768-5776.

[73]

50.

Dooley, D. J., C. P. Taylor, S. Donevan, and D. Feltner. 2007. Ca2+ channel
alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci
28:75-82.

51.

Taylor, C. P. 2009. Mechanisms of analgesia by gabapentin and pregabalin--calcium
channel alpha2-delta [Cavalpha2-delta] ligands. Pain 142:13-16.

52.

Moore, R. A., P. J. Wiffen, S. Derry, and H. J. McQuay. Gabapentin for chronic
neuropathic pain and fibromyalgia in adults. Cochrane Database Syst
Rev:CD007938.

53.

Cardenas, D. D., and M. P. Jensen. 2006. Treatments for chronic pain in persons
with spinal cord injury: A survey study. J Spinal Cord Med 29:109-117.

54.

Baidya, D. K., A. Agarwal, P. Khanna, and M. K. Arora. Pregabalin in acute and
chronic pain. J Anaesthesiol Clin Pharmacol 27:307-314.

55.

Hurlbert, R. J., and M. G. Hamilton. 2008. Methylprednisolone for acute spinal cord
injury: 5-year practice reversal. Can J Neurol Sci 35:41-45.

56.

DuPen, A., D. Shen, and M. Ersek. 2007. Mechanisms of opioid-induced tolerance
and hyperalgesia. Pain Manag Nurs 8:113-121.

57.

Kuck, N. A., and M. Forbes. 1973. Uptake of minocycline and tetracycline by
tetracycline-susceptible and -resistant bacteria. Antimicrob Agents Chemother
3:662-664.

58.

Kim, H. S., and Y. H. Suh. 2009. Minocycline and neurodegenerative diseases.
Behav Brain Res 196:168-179.

59.

Stirling, D. P., K. M. Koochesfahani, J. D. Steeves, and W. Tetzlaff. 2005.
Minocycline as a neuroprotective agent. Neuroscientist 11:308-322.

[74]

60.

Brundula, V., N. B. Rewcastle, L. M. Metz, C. C. Bernard, and V. W. Yong. 2002.
Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy
for multiple sclerosis. Brain 125:1297-1308.

61.

Zhu, S., I. G. Stavrovskaya, M. Drozda, B. Y. Kim, V. Ona, M. Li, S. Sarang, A. S.
Liu, D. M. Hartley, D. C. Wu, S. Gullans, R. J. Ferrante, S. Przedborski, B. S.
Kristal, and R. M. Friedlander. 2002. Minocycline inhibits cytochrome c release and
delays progression of amyotrophic lateral sclerosis in mice. Nature 417:74-78.

62.

Teng, Y. D., H. Choi, R. C. Onario, S. Zhu, F. C. Desilets, S. Lan, E. J. Woodard, E.
Y. Snyder, M. E. Eichler, and R. M. Friedlander. 2004. Minocycline inhibits
contusion-triggered mitochondrial cytochrome c release and mitigates functional
deficits after spinal cord injury. Proc Natl Acad Sci U S A 101:3071-3076.

63.

Luccarini, I., C. Ballerini, T. Biagioli, F. Biamonte, A. Bellucci, M. C. Rosi, C.
Grossi, L. Massacesi, and F. Casamenti. 2008. Combined treatment with atorvastatin
and minocycline suppresses severity of EAE. Exp Neurol 211:214-226.

64.

Smith, C. J., H. Sayles, T. R. Mikuls, and K. Michaud. Minocycline and doxycycline
therapy in community patients with rheumatoid arthritis: prescribing patterns,
patient-level determinants of use, and patient-reported side effects. Arthritis Res
Ther 13:R168.

65.

Yune, T. Y., J. Y. Lee, G. Y. Jung, S. J. Kim, M. H. Jiang, Y. C. Kim, Y. J. Oh, G. J.
Markelonis, and T. H. Oh. 2007. Minocycline alleviates death of oligodendrocytes
by inhibiting pro-nerve growth factor production in microglia after spinal cord
injury. J Neurosci 27:7751-7761.

[75]

66.

Festoff, B. W., S. Ameenuddin, P. M. Arnold, A. Wong, K. S. Santacruz, and B. A.
Citron. 2006. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase
protease expression early after spinal cord injury. J Neurochem 97:1314-1326.

67.

Lee, S. M., T. Y. Yune, S. J. Kim, D. W. Park, Y. K. Lee, Y. C. Kim, Y. J. Oh, G. J.
Markelonis, and T. H. Oh. 2003. Minocycline reduces cell death and improves
functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma
20:1017-1027.

68.

Bocker, R., C. J. Estler, and D. Ludewig-Sandig. 1991. Evaluation of the hepatotoxic
potential of minocycline. Antimicrob Agents Chemother 35:1434-1436.

69.

Goldstein, N. S., N. Bayati, A. L. Silverman, and S. C. Gordon. 2000. Minocycline
as a cause of drug-induced autoimmune hepatitis. Report of four cases and
comparison with autoimmune hepatitis. Am J Clin Pathol 114:591-598.

70.

Knowles, S. R., L. Shapiro, and N. H. Shear. 1996. Serious adverse reactions
induced by minocycline. Report of 13 patients and review of the literature. Arch
Dermatol 132:934-939.

71.

Malcolm, A., T. R. Heap, R. P. Eckstein, and M. R. Lunzer. 1996. Minocyclineinduced liver injury. Am J Gastroenterol 91:1641-1643.

72.

Teitelbaum, J. E., A. R. Perez-Atayde, M. Cohen, A. Bousvaros, and M. M. Jonas.
1998. Minocycline-related autoimmune hepatitis: case series and literature review.
Arch Pediatr Adolesc Med 152:1132-1136.

73.

Gerson, D. M., and M. J. Robinson. 2006. Black pigmentation of atherosclerotic
plaques associated with chronic minocycline therapy. Cardiovasc Pathol 15:168-170.

[76]

74.

Gordon, P. H., D. H. Moore, R. G. Miller, J. M. Florence, J. L. Verheijde, C.
Doorish, J. F. Hilton, G. M. Spitalny, R. B. MacArthur, H. Mitsumoto, H. E. Neville,
K. Boylan, T. Mozaffar, J. M. Belsh, J. Ravits, R. S. Bedlack, M. C. Graves, L. F.
McCluskey, R. J. Barohn, and R. Tandan. 2007. Efficacy of minocycline in patients
with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol
6:1045-1053.

75.

Hama, A., and J. Sagen. 2007. Behavioral characterization and effect of clinical
drugs in a rat model of pain following spinal cord compression. Brain Res 1185:117128.

76.

Basso, D. M., M. S. Beattie, and J. C. Bresnahan. 1995. A sensitive and reliable
locomotor rating scale for open field testing in rats. J Neurotrauma 12:1-21.

77.

Basso, D. M., M. S. Beattie, and J. C. Bresnahan. 1996. Graded histological and
locomotor outcomes after spinal cord contusion using the NYU weight-drop device
versus transection. Exp Neurol 139:244-256.

78.

Chaplan, S. R., F. W. Bach, J. W. Pogrel, J. M. Chung, and T. L. Yaksh. 1994.
Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods
53:55-63.

79.

Christensen, M. D., and C. E. Hulsebosch. 1997. Chronic central pain after spinal
cord injury. J Neurotrauma 14:517-537.

80.

Dixon, W. J. 1980. Efficient analysis of experimental observations. Annu Rev
Pharmacol Toxicol 20:441-462.

[77]

81.

Crown, E. D., Z. Ye, K. M. Johnson, G. Y. Xu, D. J. McAdoo, K. N. Westlund, and
C. E. Hulsebosch. 2005. Upregulation of the phosphorylated form of CREB in
spinothalamic tract cells following spinal cord injury: relation to central neuropathic
pain. Neurosci Lett 384:139-144.

82.

Crown, E. D., Z. Ye, K. M. Johnson, G. Y. Xu, D. J. McAdoo, and C. E. Hulsebosch.
2006. Increases in the activated forms of ERK 1/2, p38 MAPK, and CREB are
correlated with the expression of at-level mechanical allodynia following spinal cord
injury. Exp Neurol 199:397-407.

83.

Xu, G. Y., M. G. Hughes, L. Zhang, L. Cain, and D. J. McAdoo. 2005.
Administration of glutamate into the spinal cord at extracellular concentrations
reached post-injury causes functional impairments. Neurosci Lett 384:271-276.

84.

Mills, C. D., J. J. Grady, and C. E. Hulsebosch. 2001. Changes in exploratory
behavior as a measure of chronic central pain following spinal cord injury. J
Neurotrauma 18:1091-1105.

85.

Basso, D. M. 2004. Behavioral testing after spinal cord injury: congruities,
complexities, and controversies. J Neurotrauma 21:395-404.

86.

Tretheway, D., A. Jain, R. LaPoint, R. Sharma, M. Orloff, P. Milot, A. Bozorgzadeh,
and C. Ryan. 2008. Should trichrome stain be used on all post-liver transplant
biopsies with hepatitis C virus infection to estimate the fibrosis score? Liver Transpl
14:695-700.

[78]

87.

Li, L., Z. Fei, J. Ren, R. Sun, Z. Liu, Z. Sheng, L. Wang, X. Sun, J. Yu, Z. Wang,
and J. Fei. 2008. Functional imaging of interleukin 1 beta expression in
inflammatory process using bioluminescence imaging in transgenic mice. BMC
Immunol 9:49.

88.

Mosser, D. M. 2003. The many faces of macrophage activation. J Leukoc Biol
73:209-212.

89.

Siddall, P. J., D. A. Taylor, J. M. McClelland, S. B. Rutkowski, and M. J. Cousins.
1999. Pain report and the relationship of pain to physical factors in the first 6 months
following spinal cord injury. Pain 81:187-197.

90.

Waxman, S. G., and B. C. Hains. 2006. Fire and phantoms after spinal cord injury:
Na+ channels and central pain. Trends Neurosci 29:207-215.

91.

Widerstrom-Noga, E. G., R. Duncan, E. Felipe-Cuervo, and D. C. Turk. 2002.
Assessment of the impact of pain and impairments associated with spinal cord
injuries. Arch Phys Med Rehabil 83:395-404.

92.

Yong, V. W., J. Wells, F. Giuliani, S. Casha, C. Power, and L. M. Metz. 2004. The
promise of minocycline in neurology. Lancet Neurol 3:744-751.

93.

Austin, J. W., C. E. Kang, M. D. Baumann, L. Didiodato, K. Satkunendrarajah, J. R.
Wilson, G. J. Stanisz, M. S. Shoichet, and M. G. Fehlings. The effects of intrathecal
injection of a hyaluronan-based hydrogel on inflammation, scarring and
neurobehavioural outcomes in a rat model of severe spinal cord injury associated
with arachnoiditis. Biomaterials.

[79]

94.

Loubser, P. G., R. K. Narayan, K. J. Sandin, W. H. Donovan, and K. D. Russell.
1991. Continuous infusion of intrathecal baclofen: long-term effects on spasticity in
spinal cord injury. Paraplegia 29:48-64.

95.

Donovan, J. a. B., P. 2006. Parenteral Injections. Current Protocols in Immunology
73:1.6:1-10.

96.

Swart, A. M., S. Burdett, J. Ledermann, P. Mook, and M. K. Parmar. 2008. Why i.p.
therapy cannot yet be considered as a standard of care for the first-line treatment of
ovarian cancer: a systematic review. Ann Oncol 19:688-695.

97.

Zhao, P., S. G. Waxman, and B. C. Hains. 2007. Extracellular signal-regulated
kinase-regulated microglia-neuron signaling by prostaglandin E2 contributes to pain
after spinal cord injury. J Neurosci 27:2357-2368.

98.

Chang, Y. W., and S. G. Waxman. Minocycline attenuates mechanical allodynia and
central sensitization following peripheral second-degree burn injury. J Pain 11:11461154.

99.

Attal, N. [Therapeutic advances in pharmaceutical treatment of neuropathic pain].
Rev Neurol (Paris) 167:930-937.

100.

Radulovic, L. L., D. Turck, A. von Hodenberg, K. O. Vollmer, W. P. McNally, P. D.
DeHart, B. J. Hanson, H. N. Bockbrader, and T. Chang. 1995. Disposition of
gabapentin (neurontin) in mice, rats, dogs, and monkeys. Drug Metab Dispos
23:441-448.

101.

Hulsebosch, C. E., G. Y. Xu, J. R. Perez-Polo, K. N. Westlund, C. P. Taylor, and D.
J. McAdoo. 2000. Rodent model of chronic central pain after spinal cord contusion
injury and effects of gabapentin. J Neurotrauma 17:1205-1217.

[80]

102.

Emmez, H., A. O. Borcek, M. Kaymaz, F. Kaymaz, E. Durdag, S. Civi, O. Gulbahar,
S. Aykol, and A. Pasaoglu. Neuroprotective effects of gabapentin in experimental
spinal cord injury. World Neurosurg 73:729-734.

103.

Kale, A., A. O. Borcek, H. Emmez, Z. Yildirim, E. Durdag, N. Lortlar, G. Kurt, F.
Dogulu, and N. Kilic. Neuroprotective effects of gabapentin on spinal cord ischemiareperfusion injury in rabbits. J Neurosurg Spine 15:228-237.

104.

Gruenthal, M., M. Mueller, W. L. Olson, M. M. Priebe, A. M. Sherwood, and W. H.
Olson. 1997. Gabapentin for the treatment of spasticity in patients with spinal cord
injury. Spinal Cord 35:686-689.

105.

Baastrup, C., C. C. Maersk-Moller, J. R. Nyengaard, T. S. Jensen, and N. B.
Finnerup. Spinal-, brainstem- and cerebrally mediated responses at- and below-level
of a spinal cord contusion in rats: evaluation of pain-like behavior. Pain 151:670679.

106.

Urban, R., G. Scherrer, E. H. Goulding, L. H. Tecott, and A. I. Basbaum. Behavioral
indices of ongoing pain are largely unchanged in male mice with tissue or nerve
injury-induced mechanical hypersensitivity. Pain 152:990-1000.

107.

Raoult, D. 2008. Obesity pandemics and the modification of digestive bacterial flora.
Eur J Clin Microbiol Infect Dis 27:631-634.

108.

Nessler, S., R. Dodel, A. Bittner, S. Reuss, Y. Du, B. Hemmer, and N. Sommer.
2002. Effect of minocycline in experimental autoimmune encephalomyelitis. Ann
Neurol 52:689-690; author reply 690.

109.

Maddrey, W. C. 2005. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol
39:S83-89.

[81]

110.

Bauman, W. A., F. Biering-Sorensen, and A. Krassioukov. The international spinal
cord injury endocrine and metabolic function basic data set. Spinal Cord 49:10681072.

111.

Inskip, J., W. Plunet, L. Ramer, J. B. Ramsey, A. Yung, P. Kozlowski, M. Ramer,
and A. Krassioukov. Cardiometabolic risk factors in experimental spinal cord injury.
J Neurotrauma 27:275-285.

112.

Bryce, T. N., C. N. Budh, D. D. Cardenas, M. Dijkers, E. R. Felix, N. B. Finnerup, P.
Kennedy, T. Lundeberg, J. S. Richards, D. H. Rintala, P. Siddall, and E. WiderstromNoga. 2007. Pain after spinal cord injury: an evidence-based review for clinical
practice and research. Report of the National Institute on Disability and
Rehabilitation Research Spinal Cord Injury Measures meeting. J Spinal Cord Med
30:421-440.

113.

Randall, L. O., and J. J. Selitto. 1957. A method for measurement of analgesic
activity on inflamed tissue. Arch Int Pharmacodyn Ther 111:409-419.

114.

Santos-Nogueira, E., E. Redondo Castro, R. Mancuso, and X. Navarro. Randallselitto test: a new approach for the detection of neuropathic pain after spinal cord
injury. J Neurotrauma 29:898-904

[82]

CURRICULUM VITAE

Alissa Poteete was born in Wichita, Kansas on May 26, 1983, the daughter of Steve and
Sandy Poteete. After attending Bishop Carroll Catholic High School in Wichita, Kansas, she
attended Wichita State University for two years. She completed her education at the
University of Houston where she received a Bachelor of Science degree with a major in
Biology and a minor in Health in August 2008. In August of 2010 she began her graduate
studies at The University of Texas Health Science Center at Houston Graduate School of
Biomedical Sciences.

Permanent Address:
4315 La Branch, Apt 2
Houston, Texas 77004

[83]

